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ABSTRACT 
Leukemias are a cancer type which affects the leukocytes progenitor cells. These 
malignancies are highly heterogeneous in terms of molecular mechanisms 
involved in their onset and progression. Heterogeneity can be further observed 
within the same subgroup of disease at the inter-individual level, being reflected 
by different clinical outcomes and responses to treatment in different patients. 
Unfortunately, the exact leukemia aetiology is still poorly understood and 
consequently also related prevention, diagnostic, prognostic and follow up 
methods remain mainly unidentified. Therefore, early-diagnosis, together with 
specifically tailored approaches to leukemia treatment, still represents a key point 
in determining patients’ health, life quality and estimated life. Several efforts have 
been started to improve diagnosis, treatment and disease monitoring of leukemia. 
In this regard, the work presented in my PhD thesis is part of an international 
project, named “NGS-PTL: Next Generation Sequencing platform for targeted 
Personalized Therapy of Leukemia”, whose objective is the development of 
technologies for the diagnosis and prognosis of haematological cancers. According 
to the project’s objective, my thesis work aims to identify sequence variants from 
Whole Exome Sequencing data for the acute types of leukemia, to be used as 
potential biomarkers to improve therapeutic interventions and for personalize 
treatments. The work describes the setup and application of a bioinformatic 
pipeline able to identify the somatic mutations in the leukemia patients and the 
driver carrier genes, again with the result obtained by its application on all the 
samples of the project.  
The setup of the pipeline has required the identification of a set of tools to apply 
to Cancer sequencing data. In particular, selection of dedicated software to 
perform the initial pre-processing of the data guarantees the use of sequencing 
data of high quality and ensures that the subsequent analysis will be performed 
on well-generated data. Moreover, the selection of MuTect as variant caller has 
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allowed us to overcome specific problems related to the heterogeneity of Cancer 
sample. The application of these software has led us to the identification of a large 
and reliable set of somatic variants to be evaluated for the identifications of new 
biomarkers and driver genes. Then, the interpretation of the somatic variants has 
required the use of specific database and resources to correctly interpret them 
and eventually to correlate the mutations with the driving or the development of 
the leukemia. Using the available biological knowledge, we were able to select 
likely highly damaging variants, some of which already connected with leukemia 
in cancer-related sources (COSMIC, ICGC and CIViC). At the end, the discover of 
genes that drives the development of the disease was performed using three 
statistical tools on the set of annotated mutations for each leukemia type, leading 
to the identification of a total of 32 biomarkers. In conclusion, the discovery of 
potential novel biomarkers, again with the additional biological information 
provided by the specific resources applied has demonstrated the importance of 
the application of NGS in the study of Leukemic patients. 
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INTRODUCTION 
 
 
LEUKEMIA 
 
The term “leukemia” represent a group of cancers which affects the leukocytes 
progenitor cells. This malignancy occurs when alterations in the normal regulatory 
processes leading to blood cells development causing uncontrolled proliferation 
and differentiation arrest of hematopoietic stem cells in the bone marrow. 
HEMATOPOIESIS 
Blood cells formation, also called hematopoiesis, is driven by hematopoietic stem 
cells, and occurs in the bone marrow. Hematopoietic stem cells are pluripotent 
progenitor cells with the capacity of self-renewal and differentiation. The 
formation of mature and functional blood cells occurs via several consecutive cell 
divisions and maturation stages. In particular, hematopoietic stem cell can 
produce blood cells following two main different lineages, one represented by 
myeloid stem cells and the other by lymphoid stem cells (Figure 1): 
• Myeloid cells: myeloid stem cells can generate red blood cells and 
platelets. In alternative, they differentiate to myeloblasts, immature cells 
of myeloid origin. Myeloblasts can produce several types of white blood 
cells known as granulocytes, a lineage that includes neutrophils, 
eosinophils, and basophils. 
• Lymphoid cells: lymphoid stem cells differentiate to lymphoblasts, which 
can produce several types of white blood cells that are different from 
granulocytes: B lymphocytes, T lymphocytes and Natural killer cells. 
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Figure 1. Blood cell development. Blood stem cells go through several intermediate steps to generate red 
blood cells, platelets, or white blood cells. Taken from www.cancer.gov 
Blood circulates through the arteries and veins with all blood cell types, namely 
red blood cells, white blood cells and platelets, which perform different functions 
throughout the body. Red blood cells, also called erythrocytes, make up about 40 
to 50 percent of the total blood volume. Red blood cells live for approximately 120 
days before being replaced by new cells produced in the bone marrow. These cells 
contain a protein called haemoglobin, which carries oxygen throughout the body 
and deliver carbon dioxide from tissues to the lungs to be exhaled. Platelets, also 
called thrombocytes, are cell fragments rather than whole cells. They clump 
together to form clots in case a blood vessel wall is damaged. Clots traps also red 
blood cells and act as plugs to stop bleeding and serve as a base for healing of the 
injured area and tissue renovation. White blood cells, also called leukocytes, are 
much fewer in number than red blood cells. These cells constitute the human 
immune system. The 5 different subsets of white blood cells work together to 
protect the body by attacking foreign invaders, as bacteria and viruses, and 
endogenous dysregulated cells as tumors. 
LEUKEMIA CELLS 
In leukemia, the bone marrow produces abnormal white blood cells called 
leukemic cells. Leukemic cells are characterized by an altered differentiation status 
9 
 
and a dysregulated cell cycle. As a consequence, the production of these cells 
alters the physiological composition and life-cycle of blood cells (formation, 
growth, function and death) thus impairing the ability of the bone marrow to 
produce normal blood cells. Moreover, because of their dysregulated cell cycle, 
leukemia cells do not die normally when they become old or damaged but 
accumulate abnormally and crowd out the healthy blood cells. Thus, over time, 
the continue increasing number of Leukemic cells alter the normal blood function 
including its oxygen capacity, the ability to control bleeding and fight infections.  
 TYPES OF LEUKEMIA 
Leukemias are highly heterogeneous malignancies both in terms of phenotypes 
and molecular mechanisms underlying their onset and progression. Heterogeneity 
can be further observed within the same subgroup of disease at the inter-
individual level, and reflects in different clinical outcomes and responses to 
treatment. There are several ways to categorize the leukemias based on different 
criteria. One of these is the classification of leukemias on the basis of the affected 
tissues (Figure 2): 
• Myeloid Leukemia: originates from myeloid cells and it is called myeloid, 
myelogenous, or myeloblastic leukemia. 
• Lymphoid Leukemia: originates from lymphoid cells and it is called 
lymphoid, lymphoblastic, or lymphocytic leukemia.  
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Figure 2. Leukemia types. Modified from www.cancerresearchuk.org 
Leukemias can be further classified based on how quickly the disease develops and 
worsens: 
• Acute: Acute leukemia is a fast-growing cancer that usually worsen quickly, 
if not treated. The abnormal blood cells composing the acute leukemia are 
very immature blasts (lymphoblasts) that grow rapidly and cannot carry 
out the normal functions of the white blood cells they derive from.  
• Chronic: Chronic leukemia is a slower-growing cancer that worsen slowly 
over time. The number of abnormal blasts produced is low and, in general, 
these cells composing this type of leukemia are more mature and maintain 
some of the normal functions of myeloid cells. 
According to these classifications, leukemias can be sub-grouped in four main 
types: 
• Acute lymphocytic leukemia (ALL) is a condition where the bone marrow 
produces large numbers of abnormal immature lymphocytes 
(lymphoblasts). ALL can be further subdivided in different subsets. For 
example, on the basis of the lineage that the abnormal lymphoblasts 
originate from, as immature B or T lymphocytes (B-ALL or T-ALL, 
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respectively). Typically, ALL develops quite quickly (acutely) and rapidly 
becomes worse (over a few weeks or so) unless treated. 
• Acute myeloid leukemia (AML) is a condition where the bone marrow 
produces large numbers of abnormal immature white blood cells which 
are derived from a myeloid stem cell (myeloblasts). AML can be further 
subdivided on the basis of what cell type they derive from and their 
maturation stage. There are eight main subtypes of AML: M0, M1, M2, etc, 
up to M7. Typically, AML develops quite quickly (acutely) and rapidly 
becomes worse (over a few weeks or so) unless treated. 
• Chronic lymphocytic leukemia (CLL) is a condition where a subject has an 
abnormal number of dysregulated B lymphocytes. The lymphocytes look 
phenotypically normal, e.g. features visible under a microscope, but they 
do not function properly. The main reason for the accumulation of 
abnormal lymphocytes is because they have a longer life-spam as 
compared to normal lymphocytes Typically, CLL progresses very slowly 
over months or years, even without any treatment. 
• Chronic myeloid leukemia (CML) also known as chronic granulocytic 
leukemia (CGL) develops due to the accumulation of an abnormal stem 
cell subset of myeloid origin. As a consequence, there is also an expansion 
of the cells that originate from the abnormal myeloid progenitor, i.e. 
neutrophils, basophils and eosinophils, that develop into nearly-normal 
white cells, but over-accumulate in the bloodstream. Typically, CML 
develops and progresses slowly over months or years, even without 
treatment. 
Despite a preliminary diagnosis of leukemia can be made with a simple complete 
blood count, extensive testing is required to differentiate myeloid and lymphoid 
leukemia and chronic versus acute leukemia. The treatment and prognosis of 
these malignancies are extremely different between the various types of 
leukemias. Moreover, as an early treatment provides the best opportunity for 
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cure, the fast and accurate diagnosis of the right subtype of the disease is 
essential. 
 
 
THE GENETICS OF LEUKEMIA 
 
In the last decade, leukemia, as well as other cancers, have been proven to be 
essentially a condition of aberrant genetic programming [1], where changes of the 
genomic sequence in specific cells alter the structure, function, and/or expression 
of proteins that control their homeostatic processes, including cell growth, 
proliferation, differentiation, and apoptosis. The dysregulation of these critical 
functions ultimately leads to neoplastic transformation. 
As general mechanism, cancer is the result of changes occurred in the DNA 
sequence of the genome of cancer cells [2]. Human cells normally acquire random 
mutations during the course of a person’s life, and typically the human body is 
able to correct most of them. However, the continuous acquisition of genetic 
variations in individual cells may lead to the acquisition of deleterious mutations 
that confer the capability to proliferate and survive, causing the uncontrolled 
development of cancer.  
The set of differences acquired in the DNA of a cancer cell genome are called 
somatic mutations, to distinguish them from germline variants which are inherited 
from parents and are transmitted to the progeny. Also, as not all the acquired 
abnormalities are effectively involved in the development of cancer, somatic 
mutations can be differentiated between two groups, named 'driver' and 
'passenger' mutations (Figure 3). A driver mutation is a mutation directly 
implicated with the development of cancer by conferring growth advantage to the 
cancer cell, while passenger mutations do not confer clonal growth advantage 
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and, therefore, do no contribute to cancer development. Cancer subsequently 
evolves through cycles of clonal expansion, that leads to further genetic 
diversification and clonal selection. As clones and subclones expand selective 
pressures can ultimately generate a highly variable patterns of genetic diversity 
[3]. This mechanism is also implicated in development of resistance to drugs 
through selection of resistant variants and is the primary cause of therapeutic 
failure.  
 
Figure 3. The cellular lineage between a fertilized egg and a fully malignant cancer cell. [4] 
The genetic aberrances that can be found in leukemic cells are highly diverse and 
varies between the different type of leukemia. These aberrances include 
chromosomal changes like the translocation, that are caused by chromosomes 
that swap some of their DNA, leading to a part of one chromosome becomes 
attached to part of a different chromosome. Other types of chromosome changes 
include the inversion, which means that a part of a chromosome is in reverse 
order, or a deletion that indicates a partial loss of a chromosome, or a duplication 
of a chromosome or a part of it. However, not only chromosome changes but also 
single nucleotide alteration concurs in determining the patient outcome and the 
development of the disease. 
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Among the genetic aberrances that can be found in leukemia, there are several 
that characterize the development of a specific type of leukemia. CML, for 
example, is characterized by the presence of the Philadelphia chromosome, a 
translocation between chromosomes 9 and 22 in humans, resulting in a fusion 
between the 5’ end of the BCR gene and the 3’ end of the ABL1 gene [5]. Although 
the Philadelphia chromosome may be found in other types of leukemias, presence 
of a BCR-ABL1 fusion gene is an absolute diagnostic criterion for CML. Another 
type of leukemia, the CLL, is instead characterised by a different set of genetic 
lesions that are typically the 13q deletions (55%; associated with favourable 
clinical outcome), trisomy 12 (15%; associated with intermediate prognosis), 11q 
deletions (12%; associated with poor clinical outcome), 17p deletions (8%; 
associated with poor clinical outcome), and recurrent mutations (2–11%) in 
NOTCH1, SF3B1, BIRC3, TP53, and MYD88 [6], [7].  
The acute types of leukemia is more complex in terms of the genetic mechanisms 
of their development. AML can occur with somatic changes affecting some specific 
types of cells through a “two-hit” process. In other words, for leukemogenesis to 
occur, two types of mutations, or “two hits,” are needed: 1) a mutation that 
improves hematopoietic cells’ ability to proliferate (class I, including FLT3 and KIT), 
and 2) a mutation that prevents the cells from maturing (class II, including CBFB-
MYH11, CEBPA, DEK-NUP214, MLL-MLLT3, NPM1, PML-RARA, RUNX1-RUNX1T1; 
[8], [9]). However, AML is the most clinically and biologically heterogeneous type 
of leukemia, and as study of genetic variation in AML continues, the aetiology of 
this disease is continuously being modified and integrated with new types of 
mutations, including mutations in epigenetic modifiers such as IDH1, IDH2, and 
DNMT3A. Moreover, also ALL is characterized by complex types of structural 
rearrangements, copy number alterations, and mutations in specific genes (i.e. 
gene regulating lymphoid development). Approximately 20% of B-ALL cases 
harbour genetic alterations that activate kinase signalling, including 
rearrangements of the cytokine receptor gene CRLF2; rearrangements of ABL1, 
JAK2, and PDGFRB; and mutations of JAK1 and JAK2. Other class of mutation 
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includes hematopoietic regulators (ETV6 and RUNX1), tyrosine kinases, and 
epigenetic regulators [10]. Both in AML and ALL there is a lot of knowledge still to 
uncover under the genetic variability of these condition. 
Since Nowell and Hungerford identified the t(9;22) translocation (the Philadelphia 
chromosome) associated with chronic myeloid leukemia, a wealth of data has 
accumulated showing that the karyotype and mutation status of certain genes 
provide important prognostic, and in some cases, therapeutic information for 
leukemia. There are several prognostic factors that are determined by 
cytogenetics; more specifically, by acquired mutations that, once detected, make 
it possible to define the appropriate treatment for a given patient.  
Specific aberrations are used for patient risk stratification and to guide the patient 
management, ad correlate with favourable and unfavourable outcome (Table 1). 
Response Rate 
French American 
British classification 
Karyotype 
Molecular 
Change 
Low M4, M5 t(6;11)(q27;q23) AF6(6q27) 
Low M4, M5 t(10;11)(p12;p23) AF10(p12) 
Low M5 t(11;17)(q23;q21) ALL 1(11q23) 
Low M4, M5 t(11:19)(q23;p13) ELL(19p13.1) 
Low M1, M2, M4, M6 t(3;3)(q23:q26) Gene activation 
Low M0, M1, M4, M5, M6, M7 inv(3)(q21;q26) Gene activation 
Low  5;5q-  
Low  7;7q-  
Low L1 t(1:19)(q23;p13) E2A, PBX1 
Low L3 t(8;14)(q24;q11)  
Moderate L3 t(8;14)(q24;Q32) IGH, cMYC 
High M2 t(8;21)(q22;q22) ETO (8q22) 
High L1 t(9;22)(q34;q11) cABL,BCR 
High L1 t(4;11)(q21;q23) MLL, AF4 
Table 1. Leukemia karyotypes and molecular changes associated with response rate 
Despite increasing knowledge of the effects of genetic variation on prognosis of 
leukemia, these are only just few examples of genomic alterations that are related 
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to the leukemia outcome. Many others have already been detected but the 
majority of mutations that drive the development of leukemias are still not known, 
and there are few options for tailoring treatment based on known genetic 
characteristics. Therefore, mutation discovery using genome-wide strategies 
recently became the state-of-art approach to investigate the genetic alterations 
linked to leukemia, as it provides a non-biased way to identify novel causative 
mutations underlying leukocyte dysregulation. Challenges for the future are to 
comprehensively identify and experimentally validate all genetic alterations 
driving leukemogenesis and treatment failure in leukemia and to implement 
genomic profiling into the clinical setting to guide risk stratification and targeted 
therapy.  
 
 
NEXT GENERATION SEQUENCING APPLIED TO 
LEUKEMIA DIAGNOSTICS 
 
Next-generation sequencing (NGS) provides the basis for the identification of 
novel diagnostic and therapeutic strategies as it makes the sequencing of 
individual genomes accessible at a reasonable cost. During the last decade, due to 
the continuous development of sequencing technologies, the cost for sequencing 
a human genome has decreased to only about 1000$. This means that the 
sequencing technology can be used for the discovery of medically relevant 
variations present in individual patients as well as the fast and cost-efficient 
assessment of the genetic variability within cohorts of patients affected by the 
same disease. 
NGS technology provides an unprecedented view of genome sequence and 
alterations down to the single-base resolution. NGS is also extremely flexible as it 
allows to investigate either the complete genomic sequence in whole-genome 
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sequencing (WGS) or to focus on specific genomic regions of interest, such as 
protein coding genes in whole-exome sequencing (WES). In particular, WES has 
been widely used in clinical studies as it allows to concentrate on highly 
informative exonic sequences. Even if the exome represents less than 2% of the 
human genome, it is the most crucial component as mutations in the exome can 
directly affect the protein structure and function and most likely result in clinical 
phenotypes. Not surprisingly the exome contains about the 85% of known disease-
causing variants [11]. Moreover, WES is far cheaper than the WGS, allows a higher 
number of samples to be analysed per sequencing run and is thus more suitable 
to the analysis of larger cohorts of clinical samples.  
To sequence only the exons of a genome the DNA has to be processed following 
some basic steps, as shown in Figure 4:  
1. The genomic DNA is randomly sheared to construct an in vitro shotgun 
library. The library fragments are also ligated to adaptors to allow the 
subsequent sequencing. 
2. The library is enriched for sequences corresponding to exons (dark blue 
fragments) by aqueous-phase hybridization capture: the fragments are 
hybridized to biotinylated DNA or RNA baits (orange fragments) in the 
presence of blocking oligonucleotides that are complementary to the 
adaptors. 
3. Recovery of the hybridized fragments by using streptavidin-conjugated 
beads that can bind the biotins presents on the probes. The capture 
fragments are then amplified and sequenced in an NGS instrument. 
4. Reads are mapped on a reference genome and candidate somatic variants 
are identified.  
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Figure 4. Workflow for exome sequencing 
 
 
IDENTIFICATION OF SOMATIC VARIANTS 
 
The process that goes from sequencing data to a reliable set of somatic mutations 
is complicated by the presence of confounding factors such as sequencing errors, 
misalignments or repetitive sequences. To ensure the accurate detection of 
somatic variants it is necessary to perform several pre-processing of the 
sequenced reads. The step of pre-processing includes the removal of reads derived 
from PCR duplicates, the filtering of low quality reads and the removal of adaptor 
sequences. Then, methods specifically dedicated to the identification of somatic 
mutations must be applied. These methods should implement stringent filtering 
to remove false positives due to high GC content, strand bias (reads indicating a 
possible mutation only align to one DNA strand) or from poor mapping resulting 
from repetitive or low complexity sequence in the reference genome.  
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Most tumor samples, including leukemic cells, are a heterogeneous collection of 
cells, containing both normal and cancerous cells thus further challenging the 
identification of somatic mutations. Therefore, dedicated analysis methods should 
be applied to detect low frequency variants that represent the cancer cells, within 
the high background signal due to cells with normal genome. Standard variant 
callers are based on the assumption of a diploid genome in which variants are 
either present in heterozygous or homozygous state. This model does not apply 
when only a limited portion of cells in the sample show the variant. As a result, 
most of real somatic variants are just discarded as background noise. Different 
approaches have been thus implemented [12]–[14]. Among these, MuTect 
software has been successfully used to identify somatic mutations in mixed 
samples and is a widely-recognized method for somatic variant calling in cancer 
samples. While the majority of existing methods typically miss low-allelic-fraction 
mutations that occur in only a subset of the sequenced cells owing to either tumor 
heterogeneity or contamination by normal cells, MuTect is specifically created to 
detect subpopulations of variants with very low allele fractions (10%) and only a 
few reads supporting somatic mutations. 
MuTect takes as input the sequence data from the tumor and the matched normal 
DNA after alignment of data to a reference genome and standard pre-processing 
steps. MuTect applies a statistical analysis that identifies high confidence sites that 
are likely to carry somatic mutations. The analysis predicts a somatic mutation by 
using two Bayesian classifiers: the first aims to detect whether the tumor is non-
reference at a given site; for those sites that are found as non-reference, the 
second classifier makes sure that the normal sample does not carry the variant 
allele. In practice the classification is performed by calculating a LOD score (log 
odds) and comparing it to a cutoff determined by the log ratio of prior probabilities 
of the considered events.  
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For the tumor: 
???? =  ????? ? ?????????? ???? ?? ????? |???? ?? ???????)?????????? ???? ?? ????? |???? ?? ?????????)? 
For the normal: 
???? =  ????? ??????????? ???? ?? ?????? |???? ?? ?????????)?????????? ???? ?? ?????? |???? ?? ???????) ? 
Since the somatic mutations are expected to occur at a rate of ~1 per Mb, are 
required that LODr > log10(0.5x10-6)≈6.3 which guarantees that the false positive 
rate, due to noise in the tumor, is less than half of the somatic mutation rate.  In 
the normal tissue, since germline variants occur roughly at a rate of 100 per Mb, 
are required that LODN > log10(0.5x10-2)≈2.3. This cutoff guarantees that the false 
positive rate of the somatic call, namely due to the missing identification of the 
variant in the normal, is also less than half the somatic mutation rate. 
 
 
ANNOTATION AND PRIORITIZATION OF SOMATIC 
VARIANTS 
 
The first important step to assess the biological impact of a somatic mutation is to 
annotate it with the existing knowledge. In the context of exome sequencing, the 
annotation procedure starts with the identification of the protein-coding genes in 
which the variant is located and the assessment of their impact on the final protein 
product (Figure 5, Table 2).  
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Figure 5. A diagram showing the location of each type of variant 
Loss of Function The variant is likely to cause the transcript’s product to lose 
function. The ontologies included in this category are: 
transcript ablation, exon loss variant, stop lost, stop gained, 
initiator codon variant, frameshift variant, splice acceptor 
variant, splice donor variant  
Missense The variant will cause at least one amino acid to change or 
cause a premature start codon in the UTR5. The ontologies 
included in this category are: disruptive inframe deletion, 
disruptive inframe insertion, inframe deletion, inframe 
insertion, 5 prime UTR premature start codon gain variant, 
missense variant 
Other The variant is likely to have a low or unknown effect on the 
transcript’s functional product. These changes do not change 
the amino acid sequence of the protein. The ontologies 
included in this category are: synonymous variant, stop 
retained variant, splice region variant, 3 prime UTR variant, 
5 prime UTR variant, intron variant, non-coding exon variant, 
intergenic variant 
Table 2. The categories of effect among the variant transcript interaction and the likely effect that the 
variant will have on the protein’s product, including the ontologies that correspond to each effect category 
In particular, mutations that can affect the function of a protein are the non-
synonymous mutations. These include for example stop gain and frameshift 
mutations that by truncating the protein product may result in the inactivation of 
the protein. Also, missense mutations, which cause an aminoacidic sequence 
alteration, may also have an effect on protein function by altering its 3D structure 
or affecting its active site or regulatory sites. The assessment of the impact and 
the potential pathogenicity of these non-synonymous variants is the most crucial 
step in the annotation procedure and relies in the application of several 
computational methods. Prediction tools, such as SIFT [15], PolyPhen [16], 
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MutationTaster [17], MutationAssessor [18] and GERP [19], have been developed 
to estimate whether a given variant is likely to be deleterious for the function of 
the encoded protein and are based on different principles, like the conservation 
among species, the biochemical properties of the encoded amino acids and the 
three-dimensional calculations of the protein structure. Moreover, one of the 
most effective ways to enrich a somatic variants dataset for the most-likely 
damaging variants is to use a population frequency filter, based on the concept 
that causative variants are rare and therefore not common within a reference 
healthy population. Several databases such as ExAC (Exome Aggregation 
Consortium) [20], the 1000 Genome Project [21] and the NHLBI Exome Sequencing 
Project (ESP6500) [22] provide population-level variant frequencies thus allowing 
to discriminate between innocuous common variants and potentially dangerous 
rare variants.  
A further step for annotating and prioritizing variants is to use knowledge coming 
from previous studies. Several dedicated resources like the Catalogue Of Somatic 
Mutations In Cancer (COSMIC) [23], [24], the International Cancer Genome 
Consortium (ICGC) [25] data and the Clinical Interpretation of Variants in Cancer 
(CIViC) [26] database provide information about the recurrence of somatic 
mutations in cancer types and about known susceptibility/resistance to drugs 
associated to particular mutations. 
 
 
IDENTIFICATION OF DRIVER GENES 
 
Only a small subset of the somatic mutations found in cancer cells are responsible 
for tumorigenesis. The distinction of real driver mutations from passenger 
mutations is the most important task in cancer genome sequencing projects, and 
implies the identification of genes that exhibits signals of positive selection across 
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a cohort of tumor samples. Among all the different approaches utilized at this aim, 
the most intuitive consists in the identification of genes that are mutated more 
frequently than expected given a certain background mutation rate. A second 
approach is based on the observation that driver mutations tend to clusterize in 
particular regions of the proteins, like for example kinase domains. Also, this 
second method exploits positive selection signals over the background mutation 
rate to identify genes containing putative driver mutations. While these methods 
are useful to identify highly recurrent driver genes and mutations, both are 
intrinsically limited in detecting lowly recurrent drivers. A third complementary 
approach has been developed which evaluates the functional impact of the 
mutations on the protein. This method detects putative driver genes by identifying 
those mutations biased towards higher functional impact. This approach doesn’t 
rely on the estimation of a background mutation rate and is thus not limited to 
highly recurrent mutations. However, being based on assessment of the functional 
impact of mutations, it is generally more suited to the identification of loss of 
function events.  
Clearly, no method can provide a comprehensive identification of driver genes due 
to intrinsic limitations. Thus, the combination of several approaches should be 
exploited to obtain the most comprehensive list of driver genes.  
The next paragraphs are dedicated to the description of the three software 
selected for identification of driver genes in the present study which are based on 
the principles outlined above. They all require somatic variants data generated 
from a cohort of tumor samples. 
MUTSIGCV 
 
The first software selected, MutSigCV [27], works based on a recurrence-based 
approach to identify genes that are mutated more often than one would expect by 
chance. The method is based on the mutation frequency of an individual gene 
compared with the background mutation rate. The software corrects for possible 
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variations by employing patient-specific mutation frequencies and mutation 
spectra (e.g., the percentages of mutations that are transitions of certain types, 
transversions of certain types, and/or nonsense), and gene-specific mutation rates, 
incorporating expression levels and replication times.  Incorporating these 
covariates into the model substantially reduces the number of false positives in the 
generated list of significant genes. 
The following figure (Figure 6) shows how the software works: on the left a set of 
chromosomes, each from the tumor of a different cancer patient.  Genes are 
cartooned as coloured bands, and somatic mutations are indicated by red 
triangles. The mutations from all the tumors are aggregated together by merging 
the data from the different tumors, and the total number of mutations per gene 
can be computed.  Then such tally is converted to a score, and then to a 
significance level.  A threshold is chosen to control for the False Discovery Rate 
(FDR), and genes exceeding this threshold are reported as significantly mutated. 
 
Figure 6. MutSigCV procedure 
MutSigCV produces a report of significant genes, listed in descending order from 
the most significant to least significant ones. 
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ONCODRIVECLUST 
 
The second software selected, OncodriveCLUST [28], has an approach based on 
mutation clustering on protein domains. The method is designed to exploit the fact 
that mutations in cancer genes, especially oncogenes, often cluster in particular 
positions of the protein and therefore do not occur with equal probability on all 
the positions of a gene (Figure 7). Clustering within specific regions suggests they 
mutations are positively selected during the clonal tumor evolution, and might 
therefore alter the function of the protein conferring an adaptive advantage to the 
cancer cells. Such feature can thus be exploited to nominate novel candidate driver 
genes. 
 
Figure 7. Mutation clustering on specific position of a gene 
The method does not assume that the baseline mutation probability is 
homogeneous across all gene positions but creates a background model using 
silent mutations. Coding silent mutations are supposed to be under no positive 
selection and may reflect the baseline clustering of somatic mutations.  
The software works by performing four main steps: 
• mutations affecting proteins are clustered by gene across a cohort of tumor 
samples. Those protein residues having a number of mutations barely 
expected by chance are selected as candidate positions. 
• these positions are grouped to form mutation clusters 
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• each cluster is scored with a figure proportional to the percentage of the 
mutations that are enclosed within that cluster, and inversely related to its 
length. The gene clustering score is obtained as the sum of the scores of all 
clusters (if any) found in that gene 
• each gene clustering score is compared with the background model to 
obtain a significance value. The background model is obtained performing 
the same steps than above but assessing only coding silent mutations. 
 
 
ONCODRIVEFM 
 
The last software selected, OncodriveFM [29], is based on the identification of the  
functional impact of variants. It computes a metric of functional impact using three 
well-known methods (SIFT, PolyPhen2 and MutationAssessor) and assesses how 
much the functional impact of variants found in a gene across several tumor 
samples deviates from a null distribution. OncodriveFM is thus based on the 
assumption that any bias towards the accumulation of variants with high 
functional impact is an indication of positive selection and can thus be used to 
detect candidate driver genes or gene modules and to prioritize genes or 
pathways.  
The software starts by computing three metrics of functional impact (FI score) for 
each non-synonymous single nucleotide variants (nsSNVs) found in genes across a 
list of tumor samples (Figure 8). Stop-gain SNVs (stSNVs) and frameshift-causing 
indels (fsindels) are incorporated into the bias analysis by assigning them scores 
that are comparable to the highest-ranking tier of nsSNVs. Finally, synonymous 
SNVs (sSNVs) are taken into account with scores equal to those of bottom ranking 
nsSNVs. The second step starts by averaging the FI scores of variants per gene and 
comparing them to the distribution of scores of variants in functionally similar 
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genes. if the somatic SNVs are obtained using a whole-exome sequencing 
approach, the null distribution contains the entire set of SNVs and fsindels 
detected across all tumor samples. The mean FI of each gene across all tumor 
samples is then probed for significance employing a permutation strategy. 
  
Figure 8. OncoDriveFM procedure 
 
 
BACKGROUND OF THE PROJECT 
 
Leukemia accounts for approximately 10% of the new diagnosed cancers every 
year, with an overall incidence that is slightly higher in subjects of European 
ancestry. Unfortunately, despite the huge advances in the clinical treatment of 
some subtypes of leukemia, many still have a poor prognosis. In addition, in a 
subset of long-term surviving patients, treatment results are unsatisfactory for 
short and long-term toxicities. Reason of this picture is that the exact leukemia 
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aetiology is still poorly understood and consequently also related prevention, 
diagnostic, prognostic and follow up methods remain mainly unidentified. The 
early-diagnosis, together with specifically tailored approaches to leukemia 
treatment, still represents key points in determining patients’ health, life quality 
and estimated life.   
Several initiatives [30], thanks to collaborative groups and international projects, 
have been started to improve diagnosis, treatment and disease monitoring for 
leukemia. At this regard, my PhD project is part of a bigger international project, 
named NGS-PTL, “Next Generation Sequencing platform for targeted Personalized 
Therapy of Leukemia”, financed by the European Union through the seventh 
framework program. The project involved 10 international partners in a 
multidisciplinary approach, comprising the fields of clinical medicine, industry 
research, NGS technology, molecular biology, genomics, transcriptomics, 
biostatistics and bioinformatics. The objective of NGS-PTL project was the 
development and validation of methods for the diagnosis and prognosis of 
haematological cancers. These included quality control and analytical tools, based 
on the most innovative massive parallel DNA/RNA sequencing technologies. The 
NGS-PTL project aimed to provide the basis for a completely new knowledge of 
leukemia aetiology and of the molecular mechanisms underlying inter-individual 
variability in response to treatments. 
Uncovering the genomic variability among and within leukemia subtypes is of 
utmost importance to guide the therapeutic interventions on these diseases and 
constitutes the basis of the NGS-PTL project and of these work. In particular, the 
analysis reported here was focused on the main type of leukemia patients present 
in the project, that is the acute subtype of leukemia, the more complex in terms 
of the genetic mechanisms involved in their development. 
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AIM OF THE STUDY 
 
In agreement with the NGS-PTL project’s objectives, my work aimed to identify 
sequence variants from Whole Exome Sequencing data of two different types of 
leukemia (AML and ALL), to select potential biomarkers of the disease to be 
investigated in future studies to improve therapeutic interventions and to tailor 
personalize treatments.  
To obtain this result, the work performed during my PhD focused on the setup, 
validation and implementation of a bioinformatic pipeline to identify somatic 
mutations from WES data of leukemia patients and to select candidate driver 
carrier genes in the analysed samples.  
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MATERIALS AND 
METHODS 
 
 
SELECTED SAMPLES 
 
This work involved the analysis and interpretation of WES data derived from 
leukemia patients. The cohorts of patients selected belongs to two main types of 
Leukemia, the Acute Myeloid Leukemia (AML) and the Acute Lymphoblastic 
Leukemia (ALL).  The selected patients and samples are summarized in Table 3. 
Leukemia type # samples # patients 
AML 128 64 
ALL 77 37 
Table 3. Number of samples and patients for each leukemia type selected in the project 
To identify somatic variants characterizing the leukemia and unambiguously 
discriminate them from inherited germline variants, multiple samples 
corresponding to the control “normal” tissue (usually saliva) and the tumoral 
tissue (peripheral blood or bone marrow), collected at one or multiple timepoints 
(onset and relapse of disease), were sequenced for each patient. In particular, two 
cohorts of patients were selected for AML cases. The first cohort comprised 42 
cases which included 4 patients with a normal karyotype, 25 patients with one or 
two chromosomal abnormalities and 13 patients with a complex karyotype, i.e. 
with more than two chromosomal abnormalities. 34 tumoral samples were 
collected at diagnosis and 8 samples at relapse along with their matched healthy 
control samples. In the second cohort 22 cases were selected, which include 6 
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cases with a complex karyotype and the remaining with one or two chromosomal 
abnormalities. All the samples were collected at the diagnosis and after the 
complete remission of the disease. For ALL, patients negative for the typical 
Philadelphia chromosome (BCR-ABL) translocation, as well as for other known 
recurrent molecular rearrangements (i.e. E2A-PBX, TEL, AML1-MLL-AF4), were 
selected. The matched tumoral/normal samples were collected from adult B-ALL 
patients at the time of diagnosis in 33 cases, at relapse in one case, at both 
diagnosis and relapse in 3 cases.  
The preparation of the Whole Exome libraries was performed on all the 205 
samples included in the study with two Illumina kits: the TruSeq Exome Enrichment 
Kit and the Nextera Rapid Capture Exome that are based on almost identical 
capture designs for the selection of exome sequences. Sequencing was performed 
using an Illumina HiSeq1000, generating sequencing reads of 100 nucleotides in 
paired end, i.e. every DNA fragment is sequenced twice, on the forward and 
reverse strand. Each genome region analysed was sequenced on average 80 time, 
i.e. 80X coverage, to ensure the detection of mutations associated with the 
disease at high sensitivity.  
 
All the sequenced samples were analysed with the same workflow which can be 
divided into four parts:  
1. preprocessing of raw reads obtained from WES and alignment to the 
reference genome sequence; 
2. somatic variants calling;  
3. variants annotation;  
4. identification of driver-mutations carrier genes.  
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RAW READS PREPROCESSING AND ALIGNMENT 
TO REFERENCE GENOME 
 
The preprocessing pipeline was based on a set of open source tools including 
different modules dedicated to data filtering, quality control (QC) and reads 
alignment, and is based on a well-established workflow [31] as summarized in 
Figure 9.  
 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and 
NGSQCToolkit [32] applications were selected to perform sequencing data QC and 
filtering. The FastQC software v. 0.10.1 was chosen to determine sequencing data 
quality before proceeding with the analyses as it provides a fast overview of the 
level of error of produced reads potentially affecting subsequent alignment and 
SNP calling steps. Then, it was chosen to add a filtering step to remove low quality 
reads and contaminant adaptor sequences, thus increasing the accuracy of results 
obtainable from produced data. For this purpose, the NGSQC toolkit was 
employed.  
Figure 9. The preprocessing pipeline 
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For the alignment of the high quality paired-end reads to the hg19 reference 
genome the Burrows-Wheeler Aligner (BWA 0.6.2) was selected, a fast and 
memory-efficient read aligner widely used for WES alignment [33] that allows 
gapped alignment, thus enabling a more accurate alignment and detection also in 
correspondence of insertions and deletions (INDELs) [34]. The alignment data 
filtering was based on the Picard Tools (https://broadinstitute.github.io/picard/) 
to remove artifacts due to PCR duplicates. 
 
Then, Genome Analysis Toolkit suite (GATK ver. 2.5.2) [35] was selected to perform 
local re-alignment and quality score recalibration. In more details: GATK was used 
to perform a local realignment of reads in correspondence of insertions and 
deletions to avoid false calls due to wrong alignments in “challenging” genomic 
#FastQC (0.10.1) 
 
fastqc --nogroup -t 2 sequence_1.fastq.gz sequence_2.fastq.gz -o FastQC 
 
#ngsqctoolkit (2.3) 
 
perl NGSQCToolkit_v2.3/QC/IlluQC_PRLL.pl -c 24 -t 2 -s 20 -l 70 -pe sequence_1.fastq.gz 
sequence_2.fastq.gz 2 A -o sample_name/ 
#BWA (0.6.2) 
 
bwa-0.6.2/bwa aln -t 24 ucsc.hg19.fasta sequence_1_filtered.fastq.gz >sequence_1_filtered.sai 
bwa-0.6.2/bwa aln -t 24 ucsc.hg19.fasta sequence_2_filtered.fastq.gz >sequence_2_filtered.sai 
bwa-0.6.2/bwa sampe -r 
@RG\\tID:2\\tLB:flowcell\\tPL:illumina\\tSM:sample_name\\tPU:unk_barconde 
ucsc.hg19.fasta sample_name/sequence_1_filtered.sai sample_name/sequence_2_filtered.sai 
sample_name/sequence_1_filtered.fastq.gz sample_name/sequence_2_filtered.fastq.gz | 
samtools view -Sbh - >sample_name/alignment.bam 
 
#Picard (1.81) 
 
java -Xmx16g -jar picard-tools-1.81/SortSam.jar VALIDATION_STRINGENCY=SILENT 
TMP_DIR=sample_name/TMP MAX_RECORDS_IN_RAM=1000000 
INPUT=sample_name/alignment.bam OUTPUT=sample_name/alignment_sorted.bam 
SORT_ORDER=coordinate CREATE_INDEX=true 
java -Xmx16g -jar picard-tools-1.81/MarkDuplicates.jar VALIDATION_STRINGENCY=SILENT 
TMP_DIR=sample_name/TMP CREATE_INDEX=true REMOVE_DUPLICATES=true 
ASSUME_SORTED=true INPUT=sample_name/alignment_sorted.bam 
OUTPUT=sample_name/alignment_sorted_dedup.bam 
METRICS_FILE=sample_name/alignment_sorted_dedud_duplicates.txt 
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regions. In particular, we realigned reads around known INDELs annotated in the 
1000Genomes project dataset. GATK was also used to perform a recalibration of 
the quality of bases according to direct comparison with the reference genome, 
allowing to obtain more accurate results than simply relying on the base call 
accuracy measure provided by the sequencer. To avoid biases in the correction 
process, genomic positions corresponding to known variants annotated in dbSNP 
build 135 [36] were removed from the recalculation of base accuracy. 
 
 
 
VARIANT CALLING 
 
The variant calling pipeline was based on MuTect [14], a tool specifically created 
for the calling of somatic mutations in cancer samples. MuTect uses both dbSNP 
[36] and COSMIC [23], [24] to confidently call somatic variants by blacklisting 
#GATK (2.5-2) 
 
java -Xmx16g -jar GenomeAnalysisTK-2.5.2.jar -T IndelRealigner -R ucsc.hg19.fasta -I 
alignment_sorted_dedup.bam -targetIntervals hg19.intervals -o output_realigned.bam -known 
1000G_phase1.indels.hg19.orderchange.vcf -known dbsnp_135.hg19.orderchange.vcf --
consensusDeterminationModel KNOWNS_ONLY -LOD 0.4 
java -Xmx16g -jar GenomeAnalysisTK-2.5.2.jar -T BaseRecalibrator -R ucsc.hg19.fasta -I 
output_realigned.bam -o recalibrated.report -knownSites dbsnp_135.hg19.orderchange.vcf -
cov ReadGroupCovariate -cov QualityScoreCovariate -cov CycleCovariate 
java -Xmx16g -jar GenomeAnalysisTK-2.5.2.jar -T PrintReads -R ucsc.hg19.fasta -I 
output_realigned.bam -BQSR recalibrated.report -o recalibrated.bam 
 
#NGSrich (0.7.8) 
 
java -Xmx16g -cp NGSrich_0.7.8/bin/ NGSrich evaluate -r alignment_sorted_dedup.bam -u hg19 
-a refGene.txt -t capture.bed -T TMP -o CAPTURE -p 2 -h 200 --no-details 
 
#samtools (0.1.18)  
 
samtools mpileup -d 100000 -q 0 -Q 0 -f ucsc.hg19.fasta alignment_sorted_dedup.bam -A 
>alignment.mpileup 
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common polymorphism in the population and retaining known mutations 
identified also in other cancer cases. 
 
The tools, applied on all the patients’ normal and tumoral samples, produces lists 
of candidate somatic mutations as variant calling format (vcf) files. 
 
 
VARIANTS ANNOTATION 
 
The annotation of putative somatic mutations was based on the VarSeq 
(http://goldenhelix.com/products/VarSeq/) software, a tool that provide variant 
discovery and interpretation for Next Generation Sequencing data, starting from 
vcf files. 
VarSeq software were used to annotate and filter through the large variant data 
sets produced in the two different cohort of leukemia patients.  
The annotation was based on the following databases: 
• RefSeq Genes 105v2, NCBI [37]: defines genomic sequences to be used as 
reference standards for well-characterized genes. These sequences, 
labeled with the keyword RefSeqGene in NCBI's nucleotide database, 
serve as a stable foundation for reporting mutations, for establishing 
conventions for numbering exons and introns, and for defining the 
coordinates of other variations. Sequences of the RefSeqGene project 
#VARIANT_CALLING_MuTect 
 
java -Xmx2g -jar muTect-1.1.4.jar --analysis_type MuTect --reference_sequence 
ucsc.hg19.fasta --cosmic b37_cosmic_v54_120711.chr.reorder.vcf --dbsnp 
dbsnp_132_b37.leftAligned.chr.reorder.vcf --intervals all.intervals --input_file:normal 
ctrl.bam --input_file:tumor tumor.bam --out call_stats.out --coverage_file coverage.wig.txt --
vcf variants.vcf 
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provide stable gene-specific genomic sequence for each gene, as well as 
including upstream and downstream flanking regions. 
• dbSNP132 [36]: The Database of Short Genetic Variations (dbSNP) is a 
repository of all types of short genetic variations less than 50 bp in length. 
dbSNP accepts submissions of common as well as polymorphic variations, 
and contains both germline and somatic variations. In addition to archiving 
molecular details for each submission and calculating submitted variant 
locations on each genome assembly, dbSNP maintains information about 
population-specific allele frequencies and genotypes, reports the 
validation state of each variant and indicates if a variation call may be 
suspect because of paralogy. 
• 1000 Genomes - 1kG Phase3 [21]: this database contains variant 
frequencies from 1000 Genomes Project, and in particular minor allele 
frequency (MAF) for each subpopulation: Europeans, Asians, Africans and 
Admixed Americans, as well as a MAF field over all samples. These 
frequencies were calculated using 2,504 samples from the 1000 Genomes 
Project. 
• NHLBI ESP6500 Exomes Variant Frequencies [22]: this databases contains 
variant frequencies from the NHLBI Exome Sequencing Project for each 
subpopulation: European Americans and African Americans, as well as a 
MAF field over all samples. These frequencies were calculates using 6503 
samples from multiple ESP cohorts. 
• ExAC Variant Frequencies 0.3, BROAD [20]: this database contains variant 
frequencies across a combined data set of 60,706 exomes of unrelated 
individuals belonging to 7 populations (i.e. NFE – Non-Finnish European) 
sequenced as part of various disease-specific and population genetic 
studies. 
• CIViC - Variant Clinical Evidence [26]: a resource for Clinical Interpretation 
of Variants in Cancer. The database is a focused precision medicine 
resource for variants with published clinical evidence for the relationship 
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between given mutations and diagnosis, prognosis or response to a 
specific treatment of cancer. 
• COSMIC [23], [24]: the Catalogue Of Somatic Mutations In Cancer, is the 
world's largest and most comprehensive resource for exploring the impact 
of somatic mutations in human cancer. COSMIC is designed to store and 
display somatic mutation information and related details and contains 
information relating to human cancers. 
• ICGC Simple Somatic Mutations [25]: a comprehensive catalogue of 
genomic abnormalities in tumors from different cancer types and/or 
subtypes which are of clinical importance. 
• dbNSFP [38]: a database developed for functional prediction and 
annotation of all potential non-synonymous single-nucleotide variants 
(nsSNVs) in the human genome. It compiles prediction scores from 18 
prediction algorithms (SIFT, Polyphen2-HDIV, Polyphen2-HVAR, LRT, 
MutationTaster2, MutationAssessor, FATHMM, MetaSVM, MetaLR, 
CADD, VEST3, PROVEAN, FATHMM-MKL coding, fitCons, DANN, 
GenoCanyon, Eigen coding, Eigen-PC, M-CAP), 6 conservation scores 
(PhyloP x 2, phastCons x 2, GERP++ and SiPhy) and other related 
information including allele frequencies observed in the 1000 Genomes 
Project phase 3 data, UK10K cohorts data, ExAC consortium data and the 
NHLBI Exome Sequencing Project ESP6500 data, various gene IDs from 
different databases, functional descriptions of genes, gene expression and 
gene interaction information, etc. 
Using a chain of filters based on the selected annotation sources is possible to 
narrow the list of variants down to those that are most likely to be of interest 
(Figure 10).  
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Figure 10. Variants annotation and filtering 
With this workflow, we can select low frequency alterations to be evaluated at a 
deeper level by deciphering their biological significance. Moreover, the use of 
specific Cancer database enable the direct identification of mutations that inform 
targeted molecular therapies, drug sensitivity and prognosis for specific cancers. 
 
 
IDENTIFICATION OF DRIVER GENES 
 
The last step of the pipeline was aimed to the identification of driver carrier genes 
in the cohorts analysed based on somatic mutations identified. This step was 
performed applying a statistical analysis based on three distinct software 
(MutSigCV [27], OncodriveClust [28] and OncodriveFM [29]) using complementary 
and independent criteria aimed to detect positive selection signals. To maximize 
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the sensitivity of driver genes detection step the results from the three methods 
were combined.  
MUTSIGCV 
 
To run the MutSigCV module three files were necessary: 
• MAF mutation file: A Mutation Annotation Format (MAF) file is a tab-
delimited text file that lists mutations.   
• Coverage file: A tab-delimited file that gives the maximum number of bases 
covered to adequate depth in order to call mutations.  The file allows 
MutSigCV to operate assuming full coverage. 
• Covariates file: This file contains the genomic covariate data for each gene, 
for example, expression levels and DNA replication times, that will be used 
in MutSigCV to judge which genes are close to each other in mathematical 
"covariate space."  
The vcf files of each tumoral-normal pairs were converted to the MAF file required 
by the software using vcf2maf-master and VEP.  For the coverage and the 
covariates files were used the exome_full192.coverage.txt file and the 
gene.covariates.txt provided by the software. 
#VCF CONVERSION 
perl vcf2maf-master/vcf2maf.pl --vep-path VEP/ensembl-tools-release-
78/scripts/variant_effect_predictor/ --vep-data VEP/data/ --ref-fasta 
VEP/data/homo_sapiens/78_GRCh37/Homo_sapiens.GRCh37.75.dna.primary_assembly.fa --
input-vcf $vcf --output-maf ${vcf}.maf --tumor-id $tumor --normal-id $normal 
 
#MutSigCV 
 
MutSigCV_1.4/MutSigCV_1.4/run_MutSigCV.sh mutations.maf exome_full192.coverage.txt 
gene.covariates.txt mutsig mutation_type_dictionary_file.txt chr_files_hg19 1 
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ONCODRIVEFM 
 
To run OncodriveFM were necessary the files with the functional prediction for 
each tumoral-normal pair. The prediction uses were SIFT, Polyphen2 and 
MutationAssessor. 
These files were prepared using ANNOVAR and converted to the format required 
by the software. For the mappings between genes and pathways to be analysed 
were used the file ensg_kegg.tsv provided by the software. 
#FUNCTIONAL PREDICTION ANNOTATION 
annovar/convert2annovar.pl -format vcf4 -allsample -withfreq $file >${file}.avinput; 
annovar/annotate_variation.pl -filter -dbtype 1000g2014oct_all -buildver hg19 -maf 0.01 -out 
${file} ${file}.avinput annovar/humandb/ 
annovar/table_annovar.pl ${file}.hg19_ALL.sites.2014_10_filtered annovar/humandb/ -buildver 
hg19 -out ${file} -remove  --onetranscript -protocol ensGene,ljb26_all -operation g,f -nastring . 
 
#OncodriveFM 
oncodrivefm -e median -m ensg_kegg.tsv oncodrivefm.txt 
 
ONCODRIVECLUST 
 
To run OncodriveCLUST were necessary two separated list, one with the NON-
Synonymous mutations file and one with the Synonymous mutations.  
These files were prepared using the files produced with ANNOVAR [39] for 
OncodriveFM. Then were used several files provided by the software: 
CGC.phenotype.tsv that contains the Cancer Genome Consortium data; 
pfam_domains.txt that contains the gene domains and gene_transcrips.tsv that 
contains transcripts length for each gene. 
#OncodriveCLUST 
oncodriveclust -m 3 -c --cgc CGC_phenotype.tsv --dom pfam_domains.txt 
oncodrivecluster_nonsyn.txt oncodriveclust_syn.txt gene_transcripts.tsv  
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RESULTS 
 
 
PREPROCESSING RESULTS 
 
The pipeline for WES analysis was applied to all the 205 sequenced leukemia 
samples. Each sample generated on average 61.7 million of fragments (100 nt X 
2), and more than 93% of these data passed the QC filtering step, thus 
demonstrating the high quality of the generated data. The big majority of the 
filtered reads could then be mapped to the reference genome (80% on average). 
Moreover, aligned data showed a mean read depth of 86.5X and about 84% of the 
exome was represented at a minimum read depth of 10X, thus ensuring a highly 
comprehensive analysis of the whole exome. Detailed statistics of the total 
number of fragments reads, the total number of filtered and mapped fragments 
obtained for each sample are reported in Appendix 1. Detailed description on the 
average coverage after filtering and deduplication of the fragments and the 
percentage of target bases covered by at least 1, 10, 20 reads are reported in 
Appendix 2. 
 
 
VARIANT CALLING RESULTS 
 
The application of the variant calling pipeline enabled the identification of 8.208 
somatic variants in AML patients and 5.582 in ALL patients with a mean per patient 
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of 128 variants in AML and 151 in ALL. Of these, respectively 7.365 and 4.676 were 
unique, that means present only in a single patient. 
Table 4 reports the summary statistics of variant calling on the two different 
leukemia types. The table includes statistics on the variants located in the CDS 
(coding DNA sequence) or in regions involved in mRNA splicing that may change 
the aminoacidic composition of the mRNA and thus affect the final protein 
product. In addition, the table reports the loss of function/missense variants, i.e. 
the most important candidate in driving the development of cancer.  
 # Total # CDS / splicing # Loss of function / missense 
AML 
64 
patients 
128 
samples 
Unique 7.365 3.273 1.314 
Per 
patient 
(mean) 
128 51 21 
ALL 
37 
patients 
77 
samples 
Unique 4.676 1.968 808 
Per 
patient 
(mean) 
151 53 22 
Table 4. Summary statistics of variant calling: total somatic variants, somatic variants located in CDS or 
splice sites, and Loss of function / missense somatic variants. The number of variants reported are either 
the total unique ones or the average per patient. 
The bar graphs in Figure 11 and 13 show the total number of the somatic variants 
detected in each patient, with AML or ALL respectively. The pie charts in Figure 12 
and 14 indicate the percentage of somatic variants divided according to their 
location in the gene or their potential effect on the encoded protein. 
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Figure 11. Distribution of somatic variants across the AML patients 
 
Figure 12. Distribution of somatic variants according to their putative functional effect in AML 
 
Figure 13. Distribution of somatic variants across the ALL patients 
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Figure 14. Distribution of somatic variants according to their putative functional effect in ALL 
 
 
ANNOTATION RESULTS 
 
The application of the variant annotation procedure enabled us to have a first 
insight into the genes that carry more mutations in the different leukemia patients 
(Figure 15-16) and to pone the basis for the application of the last and most 
important part of the pipeline, the identification of driver genes. The total number 
of mutated genes identified were 3.956 in AML and 2.821 in ALL.  
 
Figure 15. Top 50 mutated genes in AML samples 
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Figure 16. Top 50 mutated genes in ALL samples 
As expected, some genes known to be involved in pathogenesis of leukemia and 
Cancer in general (i.e. TP53 and NRAS), were frequently mutated in the analysed 
samples, both in ALL and AML cohorts. However, some genes frequently mutated 
in the samples analysed are not associated with leukemia but are rather genes 
that accumulate more mutations in respect to the normal average rate of 
mutation (i.e. MUC2). To discriminate these types of mutations and identify the 
genes associated with leukemia it is necessary to apply a statistical analysis, as 
described in the subsequent application of tools for the discovery of driver 
candidate genes. 
Moreover, to select the most-likely damaging variants a population frequency 
filter, based on the database ExAC, 1000 Genomes and NHLBI ESP6500, was used. 
A total of 5.871 variants in AML and 4.002 in ALL had a minor allele frequency 
(MAF) lower than 1% in the three selected population frequency databases, with 
1.076 AML and 750 ALL being loss of function or missense variants.  
Among the identified variants, some hundreds were previously annotated in the 
databases that contain variants identified by previous cancer studies (COSMIC, 
ICGC and CIViC), (Table 5).  
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  COSMIC ICGC CIViC 
AML 
Total 726 2.334 14 
Lof/missense 
MAF<1% 188 178 12 
ALL 
Total 283 1.154 2 
Lof/missense 
MAF<1% 118 118 2 
Table 5. Identified Variants annotated in Cancer related databases: total number of variants and total 
number of Loss of function / missense variants with a minor allele frequency lower than 1% in the 
population frequency databases 
The figures below report the distributions of the identified variants that were 
present in the COSMIC (Figure 17-18) and in ICGC (Figure 19-20) databases, 
grouped by the origin of cancer (organ or tissue) where they found by the original 
study. These figures show that in both AML and ALL samples a huge number of 
variants were annotated in Haematopoietic and Lymphoid tissue in COSMIC and 
in the blood tissue in ICGC. A summary of these variants is reported in Table 6. 
 COSMIC ICGC 
AML 
Total 90 655 
Lof/missense 
MAF<1% 34 37 
ALL 
Total 28 322 
Lof/missense 
MAF<1% 16 19 
Table 6. Somatic variants identified by the study and annotated in Haematopoietic and Lymphoid tissue in 
or in Blood tissue in the COSMIC or ICGC database, respectively. Variants reported are the total number of 
variants and the total number of Loss of function / missense variants with a minor allele frequency lower 
than 1% in the population frequency databases 
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Figure 17. AML variants reported in COSMIC, divided by cancer origin 
 
Figure 18. ALL variants reported in COSMIC, divided by cancer origin 
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Figure 19. AML variants reported in ICGC, divided by Cancer origin 
 
Figure 20. ALL variants reported in ICGC, divided by Cancer origin 
The CIViC resource was interrogated to identify variants, among those retrieved in 
our analysis, that have been previously associated with good/bad response to a 
certain therapy or with a specific cancer outcome. Table 7 and 8 report the list of 
such variant. 
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Table 7. AML variants reported in the CIViC database. Chr:Pos, chromosome and position in the genome; 
Ref/Alt, reference and alternative alleles; Gene Name, name of the gene where the variant reside; Disease, 
phenotype associated to the variant; Drugs, treatment evidence; Evidence Type, the predictive / prognostic 
/ diagnostic association between an evidence statement and a variant; Clinical significance, the sub-type of 
evidence type that the statement presents.  
 
Table 8. ALL variants reported in the CIViC database. Chr:Pos, chromosome and position in the genome; 
Ref/Alt, reference and alternative alleles; Gene Name, name of the gene where the variant reside; 
Disease, phenotype associated to the variant; Drugs, treatment evidence; Evidence Type, the predictive / 
prognostic / diagnostic association between an evidence statement and a variant; Clinical significance, the 
sub-type of evidence type that the statement presents. 
Chr:Pos Ref/Alt Identifier Gene Name Disease Drugs Evidence Type Clinical Significance
1:115256529 T/C rs11554290 NRAS Melanoma Temozolomide Predictive Sensitivity
1:115258744 C/T rs121434596 NRAS Melanoma 17-AAG Predictive Sensitivity
2:198266834 T/C SF3B1 Breast Cancer Spliceostatin A Predictive Sensitivity
2:209113112 C/T rs121913500 IDH1 Anaplastic Oligodendroglioma AG-5198 Predictive Sensitivity
2:209113113 G/A rs121913499;rs121913501 IDH1 Acute Myeloid Leukemia GSK321
Diagnostic,Pro
gnostic,Predicti
ve
Positive,N/A,Sensitiv
ity
4:55599321 A/T rs121913507 KIT Acute Myeloid Leukemia,Systemic Mastocytosis Midostaurin Prognostic,Predictive
Poor 
Outcome,Sensitivity,
Poor Outcome
9:21975017 C/T rs3814960 CDKN2A Esophagus Squamous Cell Carcinoma Prognostic Poor Outcome
12:25398281 C/T rs112445441 KRAS Colorectal Cancer Cetuximab Predictive
Sensitivity,Sensitivit
y,Resistance or Non-
Response,Resistance 
or Non-
Response,Resistance 
or Non-Response
12:25398284 C/G
rs121913529;
rs121913531;
rs121913534
KRAS Lung Adenocarcinoma Gefitinib,Erlotinib Predictive
Resistance or Non-
Response
12:25398284 C/T
rs121913529;
rs121913531;
rs121913534
KRAS
Hairy Cell Leukemia,Lung Cancer,Non-small Cell 
Lung Carcinoma,Pancreatic Carcinoma,Colorectal 
Cancer,Pancreatic Cancer,Tumor Of Exocrine 
Pancreas,Pancreatic Ductal Carcinoma
ARRY-
142886,BEZ23
5 (NVP-
BEZ235,Dactol
isib),MK-
2206,Cetuxim
ab,Vemurafeni
b
Diagnostic,Pre
dictive,Prognos
tic
Positive,Sensitivity,S
ensitivity,Sensitivity,
Poor Outcome,Poor 
Outcome,Resistance 
or Non-
Response,Poor 
Outcome
12:25398285 C/A rs121913530 KRAS
Lung Cancer,Non-small Cell Lung 
Carcinoma,Cancer,Colorectal Cancer,Non-small Cell 
Lung Carcinoma
Selumetinib 
(AZD6244),Do
cetaxel,ARS-
853,EGFR 
Inhibitor,Gefiti
nib,Erlotinib
Diagnostic,Pre
dictive,Prognos
tic
Positive,Sensitivity,S
ensitivity,Resistance 
or Non-
Response,Poor 
Outcome
12:111884608 T/C rs3184504 SH2B3 Colorectal Cancer Predisposing Positive
15:90631838 C/T rs121913503 IDH2 Acute Myeloid Leukemia,Myelodysplastic Syndrome Prognostic Poor Outcome
17:7577538 C/T rs11540652 TP53 Breast Cancer Prognostic Poor Outcome
Chr:Pos Ref/Alt Identifier Gene Name Disease Drugs Evidence Type Clinical Significance
1:115258744 C/T rs121434596 NRAS Melanoma 17-AAG Predictive Sensitivity
12:25398284 C/T
rs121913529;rs
121913531;rs1
21913534
KRAS
Hairy Cell Leukemia,Lung 
Cancer,Non-small Cell 
Lung 
Carcinoma,Pancreatic 
Carcinoma,Colorectal 
Cancer,Pancreatic 
Cancer,Tumor Of 
Exocrine 
Pancreas,Pancreatic 
Ductal Carcinoma
ARRY-
142886,BE
Z235 (NVP-
BEZ235,D
actolisib),
MK-
2206,Cetu
ximab,Ve
murafenib
Diagnostic,Pred
ictive,Predictiv
e,Predictive,Pro
gnostic,Progno
stic,Predictive,
Prognostic
Positive,Sensitivity,S
ensitivity,Sensitivity,
Poor Outcome,Poor 
Outcome,Resistance 
or Non-
Response,Poor 
Outcome
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Among the variants identified in AML patients, three variants were already 
associated with the disease by previous studies (Table 9). These variants are 
related to the specific diagnosis and prognosis of the disease, and one of them is 
associated with the response to a specific drug, i.e. Midostaurin that in a phase II 
clinical trial shows that 60% of patients (N=89) responded to treatment. 
 
Table 9. AML variants reported in CIVIC already associated with AML 
 
 
IDENTIFICATION OF DRIVER GENES 
 
To identify genes carrying driver somatic mutations, we employed three statistical 
tools, namely MutSigCV, OncodriveFM, OncodriveCLUST, on the sets of annotated 
mutations for each leukemia type. The identified genes with signals of positive 
selection were then mapped into an interaction network using Cytoscape 3 
Reactome FI plugin. Gene modules of the interaction network were identified 
through a clustering approach and the most most significant markers within such 
modules were identified by performing an enrichment analysis to identify 
pathways involved in the tumorigenesis.  
Chr:Pos Ref/Alt Identifier Gene Name Disease Drugs
Evidence 
Type
Clinical 
Significance Evidence Statement
2:209113113G/A rs121913499;rs121913501 IDH1
Acute 
Myeloid 
Leukemia
GSK321
Diagnostic, 
Prognostic, 
Predictive
Positive, N/A, 
Sensitivity
IDH1 R132 mutation is associated with 
patients of older age, high platelet count 
during diagnosis, cytogenic normalcy and 
NPM1 mutation., IDH1 R132 mutation in 
patients with AML is not associated with any 
prognostic value compared to patients with 
wild-type IDH1.,Newly developed allosteric 
inhibitors (GSK321) of IDH1 led to 
granulocytic differentiation in-vitro and in-
vivo.
4:55599321A/T rs121913507 KIT
Acute 
Myeloid 
Leukemia
Midostaurin Prognostic Poor Outcome
In acute myloid leukemia patients, D816 
mutation is associated with earlier relapse 
and poorer prognosis than wildtype KIT.
15:90631838C/T rs121913503 IDH2
Acute 
Myeloid 
Leukemia
Prognostic, 
Prognostic
N/A, Poor 
Outcome
AML patients with IDH2 mutations such as 
R172K have event free survival and overall 
survival similar to those with wild-type 
IDH2.,In AML, patients with an IDH2 R172K 
mutation have worse overall survival 
compared to those with wild-type IDH2.
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ACUTE MYELOID LEUKEMIA 
 
A total of 64 AML patients were analysed with the selected software and 17 genes 
with signals of positive selection were identified as potential driver carriers by at 
least one bioinformatic approach (Table 10). 
Gene non-
synonymous 
mutations 
 
patient(s) 
MutSigCV 
Recurrence 
OncodriveCLUST 
Clustering 
OncodriveFM 
Functional 
Impact 
AGGF1 3 3  X  
CDC27 13 11  X  
DPY19L2 5 5  X  
FRG1 14 12 X   
FRG2B 3 1  X  
H2AFV 7 6 X X  
IDH1 3 3  X  
IDH2 3 3  X  
KRAS 7 7 X X  
KRT8 3 2  X  
MUC6 14 8  X  
NRAS 4 3  X  
PHGR1 3 2  X  
RGPD3 14 9  X  
SEC63 4 3  X  
SF3B1 5 5  X  
SMC1A 3 3  X  
Table 10. List of potential driver carriers genes identified by the statistical methods, with the total number 
of mutations and patients carrying a mutation on the indicated gene 
Of the total 17 genes identified, 14 were mapped in the functional interaction 
network with 14 linker genes. Clustering of these genes identified six modules in 
the network (Table 11, Figure 21). 
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Module Nodes in Module Node List 
0 7 GRB2,KRAS,KRT8,NRAS,PPP2CA,SOCS3,YWHAQ 
1 6 CDC27,H2AFV,HIST1H2BA,RPS27A,SEC61A2,SEC63 
2 4 CWC22,FRG1,SF3B1,SMC1A 
3 4 IDH1,IDH2,PC,PSMD12 
4 3 AGGF1,FOS,RBPJ 
5 2 MUC6,TFF1 
Table 11. The six modules identified in the interaction network of the potential driver carriers genes in the 
AML patients 
 
 
Figure 21. Interaction network of the potential driver carriers genes in the AML patients and the six modules 
identified (each indicated with a different colour). 
The methods applied have identified known leukemia pathways, like the 
NRAS/KRAS (Table 12) and IDH1/IDH2 (Table 13) interaction modules, as 
significantly enriched (FDR-adjusted p-value < 0.05) in the network, thus 
demonstrating the validity of the approach. 
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Module GeneSet FDR Nodes 
 
1 RAF/MAP 
kinase 
cascade(R) 
1.00E-03 NRAS,KRAS 
1 Ras 
signaling in 
the CD4+ 
TCR 
pathway(N) 
1.00E-03 NRAS,KRAS 
1 Signaling 
by 
Leptin(R) 
1.33E-03 NRAS,KRAS 
1 p53 
pathway 
feedback 
loops 2(P) 
1.25E-03 NRAS,KRAS 
1 EGF 
receptor 
(ErbB1) 
signaling 
pathway(N) 
1.00E-03 NRAS,KRAS 
Table 12. NRAS/KRAS module enriched in the AML patient 
Module GeneSet FDR Nodes 
 
4 2-
Oxocarboxylic 
acid 
metabolism(K) 
<1.000e-03 IDH2,IDH1 
4 Citrate cycle 
(TCA cycle)(K) 
<5.000e-04 IDH2,IDH1 
4 Glutathione 
metabolism(K) 
6.67E-04 IDH2,IDH1 
4 Biosynthesis of 
amino acids(K) 
7.50E-04 IDH2,IDH1 
4 Peroxisome(K) 1.20E-03 IDH2,IDH1 
4 Carbon 
metabolism(K) 
1.33E-03 IDH2,IDH1 
4 TCA cycle(P) 9.71E-03 IDH2 
4 Peroxisomal 
lipid 
metabolism(R) 
6.99E-02 IDH1 
Table 13. IDH1/IDH2 module enriched in the AML patient. 
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ACUTE LYMPHOBLASTIC LEUKEMIA 
 
Statistical analysis of the 38 patients affected by ALL identified 29 genes with 
signals of positive selection as potential carriers of driver mutations (Table 14). 
Gene # non-
synonymous 
mutations 
# 
patient(s) 
MUTSIG 
Recurrence 
ONCODRIVECLUST 
Clustering 
ONCODRIVEFM 
Functional 
Impact 
AGAP10 3 3  X  
ANK3 4 4  X  
ANKS1B 5 3  X  
CCDC83 4 4  X  
CFHR1 4 2  X  
CS 6 3 X   
DDN 4 4  X  
DSPP 3 2  X  
EBPL 3 2  X  
H2AFV 4 2  X  
JAK2 3 2  X  
KIF9 1 1  X  
KRAS 4 4  X  
LRP1B 3 3  X  
MUC20 9 2  X  
MYH7 3 3  X X 
NRAS 13 12 X X X 
PAX5 6 6 X X X 
PDIA4 3 3  X  
PGM1 4 2  X  
PHKG1 3 2  X  
PRKRIR 6 3 X X  
RGPD3 9 5  X  
SEC63 3 3  X  
SIRT4 2 2   X 
TMEM147 1 1  X  
TP53 4 4   X 
TTC7B 3 3  X  
ZP3 4 4  X  
Table 14. List of potential driver carriers genes selected by the statistical methods, with the total number 
of mutations and patients involved 
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Of the 29 genes identified, 20 were mapped in the functional interaction network 
with 21 linker genes. Clustering identified seven enriched modules in the network 
(Table15, Figure 22). 
Module Nodes in 
Module 
Node List 
0 11 B4GALT1,EP300,H2AFV,HDAC2,KIF9,PAX5,PRKRIR,SIN3A,STK
4,TP53,ZP3 
1 11 ANK3,EGFR,GRB2,IL2RG,JAK2,KRAS,MUC20,NRAS,SFN,SOS1,
SPTB 
2 8 C1R,CALM1,CFHR1,JUN,MYH7,PAFAH1B1,PDIA4,PHKG1 
3 4 CS,FDPS,MDH2,PGM1 
4 3 RPS27A,SEC61A2,SEC63 
5 2 APBB2,LRP1B 
6 2 DSPP,ITGB1 
Table 15. The seven modules identified in the interaction network of the potential driver carriers genes in 
the ALL patients 
 
Figure 22. Interaction network of the potential driver carriers genes in the ALL patients and the seven 
modules identified 
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Also in the case of ALL patients, the methods applied identified two known 
leukemia pathways as significantly enriched: the TP53 (table 16) and 
NRAS/KRAS/JAK2 (Table 17) interaction modules. 
Mod
ule 
GeneSet FDR Nodes 
1 Factors 
involved in 
megakaryocyte 
development 
and platelet 
production(R) 
2.30E-01 TP53,KIF9 
1 PLK3 signaling 
events(N) 
2.16E-01 TP53 
1 P53 pathway 
feedback loops 
1(P) 
1.75E-01 TP53 
1 Transcriptional 
misregulation 
in cancer(K) 
1.38E-01 TP53,PAX5 
Table 16. TP53 module enriched in the ALL patient 
 
Module GeneSet FDR Nodes 
 
2 Signaling by 
Leptin(R) 
<1.000e-
03 
NRAS,KRAS,JAK2 
2 GMCSF-
mediated 
signaling 
events(N) 
<3.333e-
04 
NRAS,KRAS,JAK2 
2 ErbB2/ErbB3 
signaling 
events(N) 
<3.333e-
04 
NRAS,KRAS,JAK2 
2 Interleukin-2 
signaling(R) 
<2.500e-
04 
NRAS,KRAS,JAK2 
2 SHP2 
signaling(N) 
<2.000e-
04 
NRAS,KRAS,JAK2 
2 Prolactin 
signaling 
pathway(K) 
<1.667e-
04 
NRAS,KRAS,JAK2 
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2 RAF/MAP 
kinase 
cascade(R) 
<1.429e-
04 
NRAS,KRAS 
2 Cholinergic 
synapse(K) 
<1.250e-
04 
NRAS,KRAS,JAK2 
2 PDGFR-beta 
signaling 
pathway(N) 
<1.111e-
04 
NRAS,KRAS,JAK2 
2 Ras signaling 
in the CD4+ 
TCR 
pathway(N) 
<1.000e-
04 
NRAS,KRAS 
Table 17. NRAS/KRAS/JAK2 module enriched in the ALL patient 
The statistical analysis led to the identification of a total of 32 markers (including 
globally 19 novel and 9 established ones) across these leukemia types as reported 
in Table 18. 
Leukemia 
type 
Genes identified 
Novel genes Established genes 
AML H2AFV, SEC63, SMC1A, AGGF1, 
CDC27, FRG1 
IDH1, IDH2, KRAS, NRAS, 
SF3B1, 
ALL TMEM147, TTC7B, ANK3, CFHR1, 
CS, H2AFV, KIF9, PHKG1, PRKRIR, 
SEC63, SIRT4, PGM1, RGPD3, 
DDN, LRP1B 
TP53, JAK2, KRAS, NRAS, 
PAX5, ANKS1B 
Table 18. Gene markers selected on statistical and network-based analysis. 
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DISCUSSION 
In the last 10 years, NGS technology became a trustworthy method to study 
diseases with a genetic basis. By enabling the discovery of disease-associated 
mutations, NGS provides the foundation for a wide range of applications in 
translational research (i.e. Cancer studies). 
The aim of the project presented was the application of WES analysis to patients 
affected by leukemia, either AML or ALL, to uncover their genetic variability and 
to find new markers to help the diagnosis and identify the prognosis of these 
malignancies. In this context, the work conducted focused on the setup and 
application of a bioinformatic pipeline that allows the identification of the somatic 
variants carried by each patient, their correlation with the available knowledge in 
the Cancer Genomics area and the identification of markers for AML and ALL 
leukemia. Given that the distinction between “driver” mutations, responsible for 
leukemia development, and “passenger” mutations is one of the greatest 
challenges in the field, one main goal of the present project was the application of 
dedicated statistics and bioinformatics strategies for the selection of the most 
relevant mutations. 
The setup of a bioinformatic pipeline that enables the identification of a reliable 
set of somatic mutations has required the selection of tools suitable for the 
analysis of NGS data derived from cancer samples. The selection of dedicated 
software to perform the initial pre-processing of the data, like removing some 
known errors due to technological bias, guarantees the use of sequencing data of 
high quality and ensures that the subsequent analysis will be performed on well-
generated data. This is of utmost importance when considering that the majority 
of variants identified occurred in only a subset of the fragments analysed, 
therefore the starting data must be as clean as possible from additional 
confounding variables. Similarly, the selection of a variant caller suitable to detect 
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low frequency variants, that represent the cancer sample, has been crucial to 
overcome specific problems related to the heterogeneity nature of cancer 
samples. Thus, the application of MuTect allowed the identification of a large and 
reliable set of somatic variants to be evaluated for the identification of new 
biomarkers and driver genes. Overall, the selection of the most suitable 
bioinformatic pipeline and its application on all the sequenced leukemia samples 
has required a substantial amount of time but has assured the generation of high 
quality data, as demonstrated by the big number of sequenced fragments that 
passed the QC filtering step and the good exome coverage obtained. 
Subsequently, the application of the variant calling pipeline has enabled the 
identification of a huge number of somatic variants, and the further selection of 
meaningful variants, e.g. with a potential impact on the gene product, previously 
associated to cancer development or enriched in driver genes. Moreover, among 
all the variants identified, 4291 variants in AML and 3237 in ALL were never 
associated to cancer previously, thus representing a good starting point for the 
discovery of novel biomarker. 
The correlation of the identified somatic variants with the biological knowledge 
present in different databases allowed to identify the variants most-likely 
responsible of leukemia development (driver mutations).  
The first database utilized at this aim was RefSeqGene that enabled us to correctly 
identify the protein-coding genes in which the variant resides and to assess its 
functional consequence on the protein product, i.e. location within the CDS or on 
splice regions, and among these the loss of function/missense variants. In addition, 
RefSeqGene allowed us to have a first insight into the genes most frequently 
mutated in the different leukemia patients and to pone the basis for the 
identification of driver genes. The results obtained were reliable as demonstrated 
by the identification of genes that have been already associated to cancer 
pathogenesis (i.e. TP53, NRAS). Most importantly, our results also highlighted 
other genes that are frequently mutated in leukemia and that were never 
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associated to this type of cancer before, these were 19 in total and included for 
example CDC27 and LRP1B. 
To further narrow down the list of relevant somatic variants, we selected those 
that: (i) were rare, i.e. had a low frequency in healthy reference populations, (ii) 
were annotated in databases collecting variants associated to cancer by previous 
studies, (iii) were enriched in driver genes as identified by selected statistical 
methods.  
Selection for frequency allowed to filter out innocuous common variants, thus 
decreasing the total number of potentially dangerous variants from 8.208 to 5.871 
and from 5.582 to 4.002, respectively for AML and ALL.  Further merging of these 
data with resources that contain variants coming from previous cancer studies, 
highlighted that a big number of variants were already associated to cancer of 
Haematopoietic and Lymphoid tissue (90 in AML and 28 in ALL) and blood (655 in 
AML and 322 in ALL), indicating that the selected somatic mutations can have an 
impact on the tissues involved in leukemia development. Moreover, interrogating 
the CIViC resource, among the variants identified in AML patients, three were 
already associated with the disease by previous studies, two of these already 
related to a poor prognosis and one of them was associated with the good 
response to a specific drug (i.e. Midostaurin). 
Overall, only with the application of the right biological knowledge we can obtain 
information of fundamental importance in the analysis of single leukemic patients, 
enabling the application of a specific tailored therapy selected on the basis of 
mutations carried by each patient. However, resources connecting mutations to 
good/bad response or prognosis are still not complete. Still, they can take great 
vantage of large sequencing project like the one presented here to obtain novel 
biomarkers that can be further validated and then used for addressing the most 
appropriate therapy on newly diagnosed patients. Therefore, the last part of the 
project was dedicated to the identification of genes that are most likely implicated 
in the development of the disease. In fact, as in the cancer genome only a small 
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subset of the somatic mutations found in the cells are responsible for 
tumorigenesis we discriminated between real driver mutations from passenger 
mutations, by identifying the genes that exhibits signals of positive selection 
across our cohort of tumour samples. To perform this task, we employed three 
statistical tools that together allowed us to obtain the most comprehensive list of 
driver genes, overcoming the intrinsic limitation of each software taken 
individually.  This analysis led to the identification of a total of 32 potential 
biomarkers (including 19 novel and 9 established ones) across all the samples. 
Subsequent enrichment analysis highlighted the genes involved in the 
tumorigenesis and demonstrated the significance of the markers identified. We 
identified pathways known to be implicated in leukemia development, like the 
NRAS/KRAS and IDH1/IDH2 modules in AML, and the TP53 and NRAS/KRAS/JAK2 
modules in ALL.  Beside these, the analysis found enriched pathways that are not 
connected with leukemia in an established manner. These include interesting 
relevant candidates that can be involved in leukemia pathogenesis:  CDC27 or Cell 
division cycle 27, is a protein involved in the regulation of the cell cycle, interesting 
in our condition because the dysregulated cell cycle progression has a critical role 
in tumorigenesis/leukemia. Indeed, in colorectal cancer CDC27 expression is 
significantly correlated with tumor progression and poor patient survival [40]; 
LRP1B or LDL receptor related protein 1B is a gene that encodes a member of the 
low density lipoprotein (LDL) receptor family. These receptors play a wide variety 
of roles in normal cell function and development due to their interactions with 
multiple ligands. LRP1B point mutations have been reported in a significant 
percentages of lung cancer [41] as well as in melanoma [42] and triple negative 
breast cancer [43]. One of the novel gene identified has a specific role in the 
activation of the immune system: PRKRIR is a protein-kinase that enhances the 
antiviral response, a crucial activity of lymphocytes [44]; even if its role in cancer 
is not well established, PRKRIR constitutes a promising candidate linking leukocyte 
dysregulation with cancer development. ANK3, ankyrin 3, is significantly mutated 
in endometrial cancer and in melanoma; it encodes for a membrane protein that 
62 
 
play key roles in activities such as cell motility, activation, proliferation, contact 
and the maintenance of specialized membrane domains; these are important 
aspects in leukocyte biology, however the role of this gene is still not well 
established in the immune system yet (http://www.tumorportal.org/ANK3).  Even 
if potentially relevant, the function of other genes identified has not been clearly 
connected with leukocyte biology or cancer development yet. Additional 
validation and functional studies will be necessary to investigate the implication 
of all the driver genes identified with leukemia pathogenesis and to define their 
role as potential biomarkers for disease prognosis and therapy response.  
In conclusion, the study demonstrated that the application of NGS, in combination 
with an appropriate analysis pipeline and integration of a-priori biological 
knowledge can lead to the discovery of novel candidate biomarkers associated 
with leukemia development. This Proof-Of-Concept study demonstrated that the 
NGS approach has the potential to be applied routinely in the clinic to obtain 
crucial unprecedented information for an accurate and quick diagnosis and to 
guide tailored interventions on these malignancies, thus leading to great 
successful improvements in this field. 
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APPENDIX 
APPENDIX 1 
Detailed statistics on the total number of fragments, the total number of filtered 
and mapped fragments. 
SAMPLE Type of Leukemia Phase 
# sequenced 
fragments 
# filtered 
fragments 
% filtered 
fragments 
# mapped 
fragments 
(dedup) 
% mapped 
fragments 
(dedup) 
Sample_187 AML diagnosis 86029887 80836959 93,96% 47000322 58,14% 
Sample_197 AML germline 78469088 73800314 94,05% 42710753,5 57,87% 
Sample_195 AML diagnosis 78449806 74032573 94,37% 41817760 56,49% 
Sample_198 AML germline 93325767 87708025 93,98% 48686117 55,51% 
Sample_63640 AML diagnosis 87484829 82236643 94,00% 50358970,5 61,24% 
Sample_199 AML germline 33193541 31281332 94,24% 18075269,5 57,78% 
Sample_A1010D  AML diagnosis 69086706 65314721 94,54% 56729435,5 86,86% 
Sample_A1010S  AML germline 86645093 82100017 94,75% 71832845,5 87,49% 
Sample_A1015Dbis AML diagnosis 53118847 49264808 92,74% 43714933 88,73% 
Sample_A1015S AML germline 22498594 21336279 94,83% 19535567,5 91,56% 
Sample_A1024D AML diagnosis 83830187 77226104 92,12% 68442084,5 88,63% 
Sample_A1024S AML germline 29505251 27385046 92,81% 24930547,5 91,04% 
Sample_A1025D AML diagnosis 82814040 77031343 93,02% 67315045 87,39% 
Sample_A1025S AML germline 37050554 34810659 93,95% 31681783 91,01% 
Sample_B1001D  AML diagnosis 93440778 88440204 94,65% 78646235,5 88,93% 
Sample_B1001S  AML germline 69010621 65256891 94,56% 56095424 85,96% 
Sample_B1006D  AML diagnosis 57177046 53442497 93,47% 49119093,5 91,91% 
Sample_B1006S  AML germline 52609965 48698395 92,56% 44955797 92,31% 
Sample_B1014D AML diagnosis 60160493 56320811 93,62% 47388697,5 84,14% 
Sample_B1014S AML germline 23647544 22551048 95,36% 20222256,5 89,67% 
Sample_B1026D AML diagnosis 53242686 49223059 92,45% 44783359,5 90,98% 
Sample_B1026S AML germline 30701851 28937816 94,25% 26493257 91,55% 
Sample_B1028D AML diagnosis 67679596 62679188 92,61% 57695404,5 92,05% 
Sample_B1028S AML germline 32019454 29889207 93,35% 26978421 90,26% 
Sample_B1034D AML diagnosis 46850219 44093577 94,12% 39288379 89,10% 
Sample_B1034S AML germline 33523945 31590080 94,23% 28797169,5 91,16% 
Sample_B1041D AML diagnosis 71839118 67324385 93,72% 45118157,5 67,02% 
Sample_B1041S AML germline 32848233 31187890 94,95% 21765124 69,79% 
Sample_B2002D  AML diagnosis 61134067 56784815 92,89% 49584603 87,32% 
Sample_B2002S  AML germline 19738373 18729571 94,89% 17008451,5 90,81% 
Sample_B2004D  AML diagnosis 56088744 52917970 94,35% 49167606 92,91% 
Sample_B2004S  AML germline 28111907 26946179 95,85% 24873949,5 92,31% 
Sample_B2005D  AML diagnosis 57235519 53642391 93,72% 49972322,5 93,16% 
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Sample_B2005S  AML germline 63612873 59342554 93,29% 55303446 93,19% 
Sample_B2007D  AML diagnosis 69080771 64543316 93,43% 57582479 89,22% 
Sample_B2007S  AML germline 48599102 45844183 94,33% 42235665 92,13% 
Sample_B2008D  AML diagnosis 105032896 99333952 94,57% 87617743,5 88,21% 
Sample_B2008S  AML germline 73277132 69388497 94,69% 58717822 84,62% 
Sample_B2009D AML diagnosis 58801391 54970978 93,49% 51158965,5 93,07% 
Sample_B2009S AML germline 25494454 24389015 95,66% 21772026,5 89,27% 
Sample_B2023D AML diagnosis 54544548 49510634 90,77% 43662810,5 88,19% 
Sample_B2023S AML germline 38761333 36047420 93,00% 33041307 91,66% 
Sample_B2030D AML diagnosis 75680896 71876934 94,97% 65051977,5 90,50% 
Sample_B2030S AML germline 30758899 28874272 93,87% 26602684 92,13% 
Sample_B2031D AML diagnosis 45091853 42613721 94,50% 34516637,5 81,00% 
Sample_B2031S AML germline 33463869 31214478 93,28% 28633463,5 91,73% 
Sample_B2033D AML diagnosis 58109645 55018734 94,68% 48513546 88,18% 
Sample_B2033S AML germline 29706329 27859919 93,78% 25190052,5 90,42% 
Sample_B2035D AML diagnosis 58664146 53482322 91,17% 25901922 48,43% 
Sample_B2035S AML germline 26572499 22463899 84,54% 14537532,5 64,72% 
Sample_B2036D AML diagnosis 64726704 61053550 94,33% 42338692,5 69,35% 
Sample_B2036S AML germline 33778194 32086004 94,99% 22891144,5 71,34% 
Sample_B2038D AML diagnosis 65972137 59428959 90,08% 28658873,5 48,22% 
Sample_B2038S AML germline 26921438 22798648 84,69% 16305353 71,52% 
Sample_B2039D AML diagnosis 97163254 90112792 92,74% 61035349,5 67,73% 
Sample_B2039S AML germline 21081975 19998906 94,86% 14794843 73,98% 
Sample_B2040D AML diagnosis 64843281 57775681 89,10% 27236564 47,14% 
Sample_B2040S AML germline 20273825 17307126 85,37% 12479748,5 72,11% 
Sample_B2042D AML diagnosis 74978250 67526872 90,06% 29543655,5 43,75% 
Sample_B2042S AML germline 25967438 21220480 81,72% 14405588,5 67,89% 
Sample_B2043D AML diagnosis 69855875 66050017 94,55% 47102706,5 71,31% 
Sample_B2043S AML germline 37540729 35563218 94,73% 26371940 74,16% 
Sample_B2045D AML diagnosis 92623304 86980410 93,91% 58169849,5 66,88% 
Sample_B2045S AML germline 30542265 24238776 79,36% 16686825 68,84% 
Sample_BO_1_NO
RM AML germline 89619176 82202942 91,72% 60051521 73,05% 
Sample_BO_1_TU
M AML diagnosis 98477692 90428863 91,83% 62565696 69,19% 
Sample_BO_2_NO
RM AML germline 97607743 89080151 91,26% 76282649,5 85,63% 
Sample_BO_2_TU
M AML diagnosis 75960151 71594138 94,25% 54179288,5 75,68% 
Sample_BO_3_NO
RM AML germline 72222284 66890991 92,62% 52344413 78,25% 
Sample_BO_3_TU
M AML diagnosis 109099258 101171451 92,73% 68545995,5 67,75% 
Sample_BO_4_NO
RM AML germline 92515480 84090264 90,89% 66530818 79,12% 
Sample_BO_4_TU
M AML diagnosis 78920647 72710447 92,13% 61073425 84,00% 
Sample_C0017D  AML diagnosis 50319837 47517598 94,43% 40631993 85,51% 
Sample_C0017S  AML germline 48194946 45866613 95,17% 37570701,5 81,91% 
Sample_C0018D AML diagnosis 58984143 55366459 93,87% 49748583,5 89,85% 
Sample_C0018S AML germline 39221812 37000622 94,34% 33555072 90,69% 
Sample_C0022D  AML diagnosis 35259151 33397766 94,72% 23259070 69,64% 
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Sample_C0022S  AML germline 63912405 60340302 94,41% 51156387,5 84,78% 
Sample_C0037D AML diagnosis 94488008 88275405 93,42% 59374776,5 67,26% 
Sample_C0037S AML germline 28720805 27268897 94,94% 18412924 67,52% 
Sample_C0046D AML diagnosis 54449789 49042273 90,07% 23639070,5 48,20% 
Sample_C0046S AML germline 36549800 28613665 78,29% 20414772 71,35% 
Sample_D0027D AML diagnosis 97188808 89872158 92,47% 81422047,5 90,60% 
Sample_D0027S AML germline 27921833 26188675 93,79% 23071968 88,10% 
Sample_NGS-41 AML diagnosis 35044972 33438164 95,42% 30424452 86,82% 
Sample_NGS-42 AML remission 52747850 50362403 95,48% 45318691 85,92% 
Sample_NGS-43 AML diagnosis 62002729 58778197 94,80% 51409926,5 82,92% 
Sample_NGS-44 AML remission 66544386 63623193 95,61% 57161486 85,90% 
Sample_NGS-45 AML diagnosis 60105835 57189266 95,15% 50944690,5 84,76% 
Sample_NGS-46 AML remission 46377420 44352327 95,63% 40157512,5 86,59% 
Sample_NGS-47 AML diagnosis 44710686 42465206 94,98% 38007728,5 85,01% 
Sample_NGS-72 AML remission 56113798 53350952 95,08% 46862905,5 83,51% 
Sample_NGS-48 AML diagnosis 70239377 66932617 95,29% 60072819,5 85,53% 
Sample_NGS-50 AML remission 51133755 48923829 95,68% 43012183,5 84,12% 
Sample_NGS-49 AML diagnosis 45664875 43335085 94,90% 38784926 84,93% 
Sample_NGS-51 AML remission 52551694 50227084 95,58% 44256613 84,22% 
Sample_NGS-52 AML diagnosis 52960850 49843970 94,11% 44606270 84,22% 
Sample_NGS-75 AML remission 49718554 47531547 95,60% 39199407,5 78,84% 
Sample_NGS-53 AML diagnosis 69720610 66279985 95,07% 56391625,5 80,88% 
Sample_NGS-58 AML remission 63391140 60221429 95,00% 52632599,5 83,03% 
Sample_NGS-55 AML diagnosis 51290687 48375549 94,32% 42652115 83,16% 
Sample_NGS-62 AML remission 56043901 52949091 94,48% 46686880 83,30% 
Sample_NGS-56 AML diagnosis 46943999 44496964 94,79% 38372700 81,74% 
Sample_NGS-63 AML remission 54464063 51293141 94,18% 44498496,5 81,70% 
Sample_NGS-57 AML diagnosis 47857451 45511606 95,10% 39548136 82,64% 
Sample_NGS-68 AML remission 46173460 43859468 94,99% 38564247,5 83,52% 
Sample_NGS-60 AML diagnosis 57006627 54066986 94,84% 46294535,5 81,21% 
Sample_NGS-64 AML remission 48716621 46025953 94,48% 40787029 83,72% 
Sample_NGS-61 AML diagnosis 50078379 47566467 94,98% 42000454 83,87% 
Sample_NGS-66 AML remission 46311032 43938076 94,88% 37348548 80,65% 
Sample_NGS-65 AML diagnosis 52686498 49943465 94,79% 44494707,5 84,45% 
Sample_NGS-69 AML remission 57206279 54138645 94,64% 46751609 81,72% 
Sample_NGS-67 AML diagnosis 78211897 73906870 94,50% 61188349 78,23% 
Sample_NGS-71 AML remission 49070392 46753791 95,28% 41374940 84,32% 
Sample_NGS-70 AML diagnosis 54161344 51721877 95,50% 45165111,5 83,39% 
Sample_NGS-76 AML remission 49044273 46051349 93,90% 40146693 81,86% 
Sample_NGS-73 AML diagnosis 46723571 44456325 95,15% 39157963,5 83,81% 
Sample_NGS-78 AML remission 51779282 49243850 95,10% 42487234,5 82,05% 
Sample_NGS-74 AML diagnosis 43731754 41819716 95,63% 36505232,5 83,48% 
Sample_NGS-77 AML remission 58431356 55362472 94,75% 48568769,5 83,12% 
Sample_NGS-79 AML diagnosis 52543744 49838707 94,85% 43896050 83,54% 
Sample_NGS-86 AML remission 58501849 55233848 94,41% 47461781,5 81,13% 
Sample_NGS-80 AML diagnosis 54283878 51514772 94,90% 44637854,5 82,23% 
Sample_NGS-84 AML remission 47408554 44922686 94,76% 37966851,5 80,08% 
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Sample_NGS-81 AML diagnosis 47142236 44761008 94,95% 38091263 80,80% 
Sample_NGS-83 AML remission 61827641 58288808 94,28% 49732448 80,44% 
Sample_NGS-82 AML diagnosis 53496665 50819253 95,00% 43817174 81,91% 
Sample_NGS-87 AML remission 57795915 54589073 94,45% 47068972 81,44% 
Sample_3FK_3D ALL diagnosis 69102695 63510395 91,91% 56638083,5 81,96% 
Sample_3FK_3n-
DNA ALL germline 71168290 68044617 95,61% 44299504,5 65,10% 
Sample_3FK_3R ALL relapse 74056049 68897070 93,03% 60441971,5 81,62% 
Sample_4PJ_4D ALL diagnosis 82005678 75615433 92,21% 66561836,5 81,17% 
Sample_4PJ_4n-
DNA ALL germline 83522059 78570586 94,07% 67061889 85,35% 
Sample_4PJ_4R ALL relapse 56120187 52157901 92,94% 47677698,5 84,96% 
Sample_6MJ_6D ALL diagnosis 93796558 88726039 94,59% 63424179 67,62% 
Sample_6MJ_6n-
DNA ALL germline 74594066 70517430 94,53% 55372132,5 74,23% 
Sample_7TK_7D ALL diagnosis 115546871 110698372 95,80% 87264041 75,52% 
Sample_7TK_7n-
DNA ALL germline 31508710 30317788 96,22% 22355056,5 70,95% 
Sample_8PB_8D ALL diagnosis 144493912 138250366 95,68% 103439036,5 71,59% 
Sample_8PB_8n-
DNA ALL germline 33950946 32565043 95,92% 24250220 71,43% 
Sample_10JN_10D ALL diagnosis 78282405 73476504 93,86% 63715601 81,39% 
Sample_10JN_10n-
DNA ALL germline 52395970 50581368 96,54% 41205248 78,64% 
Sample_10JN_10R ALL relapse 52179625 50251503 96,30% 41490644,5 79,52% 
Sample_11LT_11D ALL diagnosis 68171713 63343797 92,92% 56070575,5 82,25% 
Sample_11LT_11n-
DNA ALL germline 107990339 102501545 94,92% 84247953,5 82,19% 
Sample_554 ALL diagnosis 76073023 70944161 93,26% 59082843,5 77,67% 
Sample_1629 ALL remission 66743298 62140898 93,10% 52466472 78,61% 
Sample_616 ALL diagnosis 65266981 62255759 95,39% 53505595 81,98% 
Sample_1630 ALL remission 86137139 80646257 93,63% 67370410 78,21% 
Sample_757 ALL diagnosis 58174042 54864088 94,31% 46323110,5 79,63% 
Sample_751 ALL germline 79226798 74952067 94,60% 61823282 78,03% 
Sample_961 ALL relapse 67814593 64151051 94,60% 53359211,5 78,68% 
Sample_1009 ALL germline 64266221 59803150 93,06% 50539030,5 78,64% 
Sample_960 ALL diagnosis 50432072 48064597 95,31% 41167518,5 81,63% 
Sample_1011 ALL germline 43915140 40851423 93,02% 34663238,5 78,93% 
Sample_1258 ALL diagnosis 37795346 35867488 94,90% 31457757,5 83,23% 
Sample_1341 ALL germline 47589113 44131119 92,73% 36882800 77,50% 
Sample_1430 ALL diagnosis 69212642 65038346 93,97% 57472172 83,04% 
Sample_1612 ALL germline 39806959 36424628 91,50% 30022563 75,42% 
Sample_1731 ALL diagnosis 78217014 73709543 94,24% 40469026,5 54,90% 
Sample_1764 ALL germline 71775242 67464261 93,99% 40067253,5 59,39% 
Sample_30846 ALL diagnosis 22842232 21120132 92,46% 16758299,5 73,37% 
Sample_37839 ALL remission 73833615 69290082 93,85% 59096982,5 80,04% 
Sample_43873 ALL diagnosis 47264247 44218792 93,56% 38736814,5 81,96% 
Sample_44365 ALL remission 55070575 51881778 94,21% 44949302 81,62% 
Sample_65420 ALL diagnosis 61844155 58419603 94,46% 50899102,5 82,30% 
Sample_80535 ALL remission 33797942 32296904 95,56% 28963946,5 85,70% 
Sample_74413 ALL diagnosis 61456436 56896952 92,58% 50473434,5 82,13% 
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Sample_75147 ALL remission 66498953 62801775 94,44% 54186091,5 81,48% 
Sample_78540 ALL diagnosis 70630741 66556740 94,23% 56945706,5 80,62% 
Sample_79323 ALL remission 61267898 57987996 94,65% 50937543 83,14% 
Sample_85112_85
11 ALL diagnosis 56200834 52238366 92,95% 46670675,5 83,04% 
Sample_295012_2
950 ALL remission 84045875 79493727 94,58% 61526410 77,40% 
Sample_106013_1
060 ALL diagnosis 72166868 67908483 94,10% 57157813,5 79,20% 
Sample_125613_1
256 ALL remission 78404359 74799886 95,40% 62075663 79,17% 
Sample_108612_1
086 ALL diagnosis 61520145 56346898 91,59% 41570830,5 67,57% 
Sample_163213_1
632 ALL remission 73814210 70038317 94,88% 58797903,5 83,95% 
Sample_139213_1
392 ALL diagnosis 72104183 68514893 95,02% 57841350,5 84,42% 
Sample_206613_2
066 ALL remission 82033667 74887273 91,29% 63856239 77,84% 
Sample_246313_2
463 ALL diagnosis 65220624 59933071 91,89% 45285724 69,43% 
Sample_222313_2
223 ALL remission 72936583 68546854 93,98% 57605101 84,04% 
Sample_331212_3
312 ALL diagnosis 83285708 78051144 93,71% 65988252,5 84,54% 
Sample_9813_98 ALL remission 82262913 75133585 91,33% 63471828,5 77,16% 
Sample_417612_4
176 ALL diagnosis 99577757 90801235 91,19% 76855088,5 77,18% 
Sample_220313_2
203 ALL remission 73721238 69197354 93,86% 58648002,5 84,75% 
Sample_NGS-163 ALL diagnosis 61600192 57851857 93,92% 50864258 82,57% 
Sample_NGS-164 ALL remission 75096097 71175145 94,78% 61436921,5 81,81% 
Sample_NGS-165 ALL diagnosis 76933888 72402718 94,11% 61987837 80,57% 
Sample_NGS-166 ALL remission 84328301 79798479 94,63% 68830342 81,62% 
Sample_NGS-167 ALL diagnosis 75085497 70816928 94,32% 61954525 82,51% 
Sample_NGS-168 ALL remission 73798144 69516131 94,20% 60531899,5 82,02% 
Sample_NGS-169 ALL diagnosis 80236416 75162117 93,68% 66265720 82,59% 
Sample_NGS-170 ALL remission 81078668 76072642 93,83% 65590191,5 80,90% 
Sample_NGS-171 ALL diagnosis 82945032 77645159 93,61% 67768557 81,70% 
Sample_NGS-172 ALL remission 77979291 73287041 93,98% 62700968 80,41% 
Sample_NGS-173 ALL diagnosis 69375244 64936228 93,60% 54730042 78,89% 
Sample_NGS-174 ALL remission 71649494 67329539 93,97% 57425696,5 80,15% 
Sample_NGS-175 ALL diagnosis 74944867 69980509 93,38% 61626636,5 82,23% 
Sample_NGS-176 ALL remission 84447221 78745042 93,25% 68133005,5 80,68% 
Sample_NGS-177 ALL diagnosis 75834804 70670030 93,19% 60997932 80,44% 
Sample_NGS-178 ALL remission 98919493 92024101 93,03% 81883933 82,78% 
Sample_NGS-179 ALL diagnosis 72307302 67221669 92,97% 58799351,5 81,32% 
Sample_NGS-180 ALL remission 64732993 60461248 93,40% 53127906 82,07% 
Sample_NGS-183 ALL diagnosis 85964106 79844085 92,88% 69671995,5 87,26% 
Sample_NGS-185 ALL germline 74741371 69352722 92,79% 60146480 86,73% 
  MEAN 61672249,64 57795861,64 93,64% 47478769,62 80,01% 
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APPENDIX 2 
Detailed description on average coverage after filtering and deduplication of the 
fragments and the percentage of target bases covered by at least 1, 10, 20 reads. 
SAMPLE Type of Leukemia Phase Coverage Mean Covered 1x Covered 10x Covered 20x 
Sample_187 AML diagnosis 94,91 95,05% 87,70% 81,82% 
Sample_197 AML germline 83,6 95,09% 87,67% 81,59% 
Sample_195 AML diagnosis 84,39 94,70% 86,22% 78,83% 
Sample_198 AML germline 95,49 95,61% 88,76% 83,47% 
Sample_63640 AML diagnosis 98,95 95,32% 88,59% 83,61% 
Sample_199 AML germline 37,64 92,67% 76,16% 59,54% 
Sample_A1010D  AML diagnosis 94,35 94,31% 87,64% 83,37% 
Sample_A1010S  AML germline 120,94 95,00% 89,03% 85,71% 
Sample_A1015Dbis AML diagnosis 73,51 97,11% 93,08% 89,12% 
Sample_A1015S AML germline 33,65 96,10% 85,55% 65,10% 
Sample_A1024D AML diagnosis 112,66 97,76% 94,46% 91,94% 
Sample_A1024S AML germline 42,39 96,54% 88,14% 72,30% 
Sample_A1025D AML diagnosis 112,47 97,66% 94,41% 91,92% 
Sample_A1025S AML germline 49,97 96,98% 90,61% 79,26% 
Sample_B1001D  AML diagnosis 133,16 95,44% 89,68% 86,55% 
Sample_B1001S  AML germline 95,53 94,75% 88,21% 84,18% 
Sample_B1006D  AML diagnosis 82,19 97,15% 93,48% 89,94% 
Sample_B1006S  AML germline 69,05 97,50% 93,03% 87,91% 
Sample_B1014D AML diagnosis 72,94 97,54% 93,17% 89,34% 
Sample_B1014S AML germline 34,14 96,46% 87,99% 72,72% 
Sample_B1026D AML diagnosis 74,57 97,14% 93,10% 88,99% 
Sample_B1026S AML germline 45,15 96,47% 89,37% 76,53% 
Sample_B1028D AML diagnosis 98,69 97,21% 93,77% 90,75% 
Sample_B1028S AML germline 44,54 96,41% 89,52% 77,16% 
Sample_B1034D AML diagnosis 67,45 96,88% 92,78% 88,19% 
Sample_B1034S AML germline 48,91 96,59% 89,88% 78,20% 
Sample_B1041D AML diagnosis 78,94 97,17% 89,52% 81,58% 
Sample_B1041S AML germline 44,51 94,57% 76,91% 61,52% 
Sample_B2002D  AML diagnosis 82,46 97,25% 93,48% 89,78% 
Sample_B2002S  AML germline 29,89 95,99% 82,64% 58,92% 
Sample_B2004D  AML diagnosis 81,72 96,04% 90,67% 85,98% 
Sample_B2004S  AML germline 42,1 96,69% 89,94% 79,30% 
Sample_B2005D  AML diagnosis 83,34 97,18% 93,05% 89,24% 
Sample_B2005S  AML germline 85,2 97,66% 93,47% 89,84% 
Sample_B2007D  AML diagnosis 95,64 97,56% 94,19% 91,10% 
Sample_B2007S  AML germline 70,33 96,14% 90,30% 85,16% 
Sample_B2008D  AML diagnosis 145,33 94,19% 88,58% 85,60% 
Sample_B2008S  AML germline 98,77 94,23% 87,58% 83,45% 
Sample_B2009D AML diagnosis 85,45 97,27% 93,29% 89,30% 
Sample_B2009S AML germline 36,81 96,74% 88,77% 74,72% 
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Sample_B2023D AML diagnosis 73,05 97,17% 93,13% 89,08% 
Sample_B2023S AML germline 55,79 96,78% 90,99% 81,51% 
Sample_B2030D AML diagnosis 111,22 97,33% 94,11% 91,47% 
Sample_B2030S AML germline 44,95 96,52% 89,04% 75,07% 
Sample_B2031D AML diagnosis 58,48 96,84% 92,16% 86,85% 
Sample_B2031S AML germline 45,93 96,78% 90,01% 78,23% 
Sample_B2033D AML diagnosis 81,08 97,15% 93,41% 89,73% 
Sample_B2033S AML germline 42,91 96,44% 88,58% 73,98% 
Sample_B2035D AML diagnosis 50,41 96,69% 85,36% 69,42% 
Sample_B2035S AML germline 29,93 94,41% 69,95% 47,53% 
Sample_B2036D AML diagnosis 75,14 97,37% 89,70% 81,55% 
Sample_B2036S AML germline 47,5 94,56% 77,85% 63,01% 
Sample_B2038D AML diagnosis 55,5 96,80% 87,09% 73,14% 
Sample_B2038S AML germline 32,88 95,35% 76,24% 53,29% 
Sample_B2039D AML diagnosis 108,58 97,96% 92,24% 87,44% 
Sample_B2039S AML germline 30,64 94,48% 72,38% 52,39% 
Sample_B2040D AML diagnosis 52,88 96,89% 86,57% 71,24% 
Sample_B2040S AML germline 25,18 94,56% 68,19% 42,91% 
Sample_B2042D AML diagnosis 58,38 96,75% 86,86% 72,82% 
Sample_B2042S AML germline 29,33 95,08% 71,46% 47,59% 
Sample_B2043D AML diagnosis 81,73 97,51% 90,48% 83,44% 
Sample_B2043S AML germline 52,59 96,22% 84,86% 70,47% 
Sample_B2045D AML diagnosis 101,18 97,64% 91,29% 85,91% 
Sample_B2045S AML germline 34,05 95,61% 77,40% 54,06% 
Sample_BO_1_NORM AML germline 165,58 99,62% 98,75% 96,97% 
Sample_BO_1_TUM AML diagnosis 172,8 99,59% 98,60% 96,71% 
Sample_BO_2_NORM AML germline 218,14 99,61% 99,12% 98,46% 
Sample_BO_2_TUM AML diagnosis 147,06 99,59% 98,44% 96,08% 
Sample_BO_3_NORM AML germline 143,78 99,52% 98,42% 96,16% 
Sample_BO_3_TUM AML diagnosis 187,36 99,52% 98,69% 97,14% 
Sample_BO_4_NORM AML germline 140,32 99,50% 98,32% 95,85% 
Sample_BO_4_TUM AML diagnosis 166,12 99,52% 98,47% 96,52% 
Sample_C0017D  AML diagnosis 68,72 93,59% 85,82% 80,12% 
Sample_C0017S  AML germline 67,59 93,66% 85,96% 80,67% 
Sample_C0018D AML diagnosis 81,1 97,39% 93,39% 89,83% 
Sample_C0018S AML germline 56,6 96,71% 91,40% 83,29% 
Sample_C0022D  AML diagnosis 39,66 92,92% 82,71% 73,31% 
Sample_C0022S  AML germline 79,37 94,21% 86,59% 81,57% 
Sample_C0037D AML diagnosis 102,52 97,88% 91,88% 87,09% 
Sample_C0037S AML germline 38,51 92,91% 70,39% 55,72% 
Sample_C0046D AML diagnosis 46,33 96,24% 82,91% 64,54% 
Sample_C0046S AML germline 40,75 96,54% 82,43% 62,12% 
Sample_D0027D AML diagnosis 133,84 97,77% 94,47% 92,36% 
Sample_D0027S AML germline 38,46 96,27% 88,22% 74,06% 
Sample_NGS-41 AML diagnosis 51.96 96,19% 88,81% 78,60% 
Sample_NGS-42 AML remission 80.28 96,60% 91,49% 86,87% 
Sample_NGS-43 AML diagnosis 87.66 97,05% 92,19% 88,08% 
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Sample_NGS-44 AML remission 99.82 96,94% 92,48% 88,90% 
Sample_NGS-45 AML diagnosis 87.99 96,85% 92,01% 87,86% 
Sample_NGS-46 AML remission 67.97 96,63% 90,79% 84,77% 
Sample_NGS-47 AML diagnosis 64.64 96,90% 90,98% 84,53% 
Sample_NGS-72 AML remission 73.79 97,28% 91,77% 86,54% 
Sample_NGS-48 AML diagnosis 93.29 97,71% 92,50% 88,52% 
Sample_NGS-50 AML remission 73.55 96,79% 91,46% 86,19% 
Sample_NGS-49 AML diagnosis 61.47 96,96% 90,96% 84,35% 
Sample_NGS-51 AML remission 73.72 96,83% 91,53% 86,53% 
Sample_NGS-52 AML diagnosis 76.74 96,86% 91,56% 86,58% 
Sample_NGS-75 AML remission 65.45 96,85% 91,06% 85,35% 
Sample_NGS-53 AML diagnosis 97.43 96,92% 92,52% 89,19% 
Sample_NGS-58 AML remission 89.76 96,95% 92,20% 88,49% 
Sample_NGS-55 AML diagnosis 75.76 96,58% 91,36% 86,57% 
Sample_NGS-62 AML remission 80.99 96,80% 91,77% 87,39% 
Sample_NGS-56 AML diagnosis 67.36 96,46% 90,75% 84,63% 
Sample_NGS-63 AML remission 77.82 96,47% 91,30% 86,55% 
Sample_NGS-57 AML diagnosis 68.47 96,87% 91,31% 85,52% 
Sample_NGS-68 AML remission 66.97 96,62% 91,14% 85,38% 
Sample_NGS-60 AML diagnosis 81.18 96,63% 91,60% 86,91% 
Sample_NGS-64 AML remission 71.2 96,49% 91,29% 86,09% 
Sample_NGS-61 AML diagnosis 72.1 96,71% 91,40% 86,10% 
Sample_NGS-66 AML remission 65.31 96,65% 90,81% 84,87% 
Sample_NGS-65 AML diagnosis 76.65 96,71% 91,35% 86,25% 
Sample_NGS-69 AML remission 81.39 96,72% 91,61% 86,90% 
Sample_NGS-67 AML diagnosis 104.59 97,11% 92,88% 89,79% 
Sample_NGS-71 AML remission 71.57 96,75% 91,23% 85,62% 
Sample_NGS-70 AML diagnosis 75.87 96,84% 91,59% 86,74% 
Sample_NGS-76 AML remission 64.91 97,10% 91,70% 85,74% 
Sample_NGS-73 AML diagnosis 62.81 96,98% 90,78% 83,69% 
Sample_NGS-78 AML remission 72.45 96,93% 91,43% 85,96% 
Sample_NGS-74 AML diagnosis 60.37 96,89% 90,72% 83,30% 
Sample_NGS-77 AML remission 82.65 97,08% 91,86% 86,93% 
Sample_NGS-79 AML diagnosis 76.59 96,78% 91,55% 86,55% 
Sample_NGS-86 AML remission 82.14 96,99% 92,07% 87,56% 
Sample_NGS-80 AML diagnosis 77.79 96,84% 91,56% 86,72% 
Sample_NGS-84 AML remission 65.29 96,82% 91,05% 84,95% 
Sample_NGS-81 AML diagnosis 65.52 96,76% 90,91% 84,75% 
Sample_NGS-83 AML remission 83.64 97,18% 92,57% 88,48% 
Sample_NGS-82 AML diagnosis 74.9 96,84% 91,59% 86,66% 
Sample_NGS-87 AML remission 80.89 96,85% 91,88% 87,51% 
Sample_3FK_3D ALL diagnosis 97,23 97,28% 92,88% 89,44% 
Sample_3FK_3n-DNA ALL germline 79,52 96,56% 91,54% 84,87% 
Sample_3FK_3R ALL relapse 104,01 97,14% 92,98% 89,58% 
Sample_4PJ_4D ALL diagnosis 106,45 97,76% 93,18% 90,15% 
Sample_4PJ_4n-DNA ALL germline 118,41 97,12% 93,28% 90,37% 
Sample_4PJ_4R ALL relapse 76,45 97,34% 92,77% 87,51% 
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Sample_6MJ_6D ALL diagnosis 111,26 97,09% 93,60% 91,13% 
Sample_6MJ_6n-DNA ALL germline 97,89 97,11% 93,07% 89,82% 
Sample_7TK_7D ALL diagnosis 148,81 97,74% 94,68% 92,57% 
Sample_7TK_7n-DNA ALL germline 40,71 95,68% 87,20% 72,64% 
Sample_8PB_8D ALL diagnosis 171,94 98,16% 95,16% 93,28% 
Sample_8PB_8n-DNA ALL germline 44,61 95,35% 82,91% 66,91% 
Sample_10JN_10D ALL diagnosis 106,68 97,40% 92,79% 89,52% 
Sample_10JN_10n-
DNA ALL germline 75,12 96,46% 91,37% 86,35% 
Sample_10JN_10R ALL relapse 74,53 96,68% 91,66% 86,73% 
Sample_11LT_11D ALL diagnosis 96,88 96,86% 92,47% 88,93% 
Sample_11LT_11n-
DNA ALL germline 147,17 97,14% 92,38% 87,33% 
Sample_554 ALL diagnosis 101,94 97,06% 92,67% 89,54% 
Sample_1629 ALL remission 93,51 96,88% 92,23% 88,59% 
Sample_616 ALL diagnosis 92,17 96,98% 92,27% 88,59% 
Sample_1630 ALL remission 118,89 97,24% 93,14% 90,40% 
Sample_757 ALL diagnosis 80,27 96,77% 91,68% 87,24% 
Sample_751 ALL germline 113,37 96,62% 91,88% 88,69% 
Sample_961 ALL relapse 91,90 97,11% 92,42% 88,72% 
Sample_1009 ALL germline 90,52 96,63% 91,82% 87,90% 
Sample_960 ALL diagnosis 71,34 96,56% 91,20% 85,99% 
Sample_1011 ALL germline 60,94 96,25% 89,94% 82,41% 
Sample_1258 ALL diagnosis 54,47 96,07% 89,67% 81,60% 
Sample_1341 ALL germline 64,50 96,52% 90,67% 84,43% 
Sample_1430 ALL diagnosis 100,66 97,00% 92,43% 88,85% 
Sample_1612 ALL germline 52,95 96,20% 89,98% 82,35% 
Sample_1731 ALL diagnosis 80,81 95,02% 86,82% 79,29% 
Sample_1764 ALL germline 80,27 95,28% 87,57% 80,39% 
Sample_30846 ALL diagnosis 28,32 96,00% 78,22% 52,40% 
Sample_37839 ALL remission 105,28 96,87% 92,53% 89,43% 
Sample_43873 ALL diagnosis 62,19 97,32% 90,72% 82,83% 
Sample_44365 ALL remission 75,22 97,05% 91,63% 86,52% 
Sample_65420 ALL diagnosis 89,17 96,76% 91,92% 87,91% 
Sample_80535 ALL remission 49,95 96,27% 89,17% 79,30% 
Sample_74413 ALL diagnosis 89,47 96,71% 92,01% 88,14% 
Sample_75147 ALL remission 96,55 96,85% 92,29% 88,86% 
Sample_78540 ALL diagnosis 99,56 97,12% 92,50% 88,90% 
Sample_79323 ALL remission 85,59 97,24% 92,07% 87,54% 
Sample_85112_8511 ALL diagnosis 80,83 96,81% 91,97% 87,70% 
Sample_295012_2950 ALL remission 108,78 97,13% 93,28% 90,47% 
Sample_106013_1060 ALL diagnosis 96,33 97,12% 92,95% 89,31% 
Sample_125613_1256 ALL remission 107,96 97,03% 93,19% 90,19% 
Sample_108612_1086 ALL diagnosis 71,70 96,88% 92,07% 87,69% 
Sample_163213_1632 ALL remission 102,49 97,04% 93,11% 89,92% 
Sample_139213_1392 ALL diagnosis 98,17 97,21% 93,11% 89,49% 
Sample_206613_2066 ALL remission 108,11 97,34% 93,48% 90,56% 
Sample_246313_2463 ALL diagnosis 78,73 96,87% 92,03% 87,67% 
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Sample_222313_2223 ALL remission 98,54 97,19% 93,26% 89,91% 
Sample_331212_3312 ALL diagnosis 112,34 97,26% 93,42% 90,41% 
Sample_9813_98 ALL remission 109,34 97,24% 93,29% 90,51% 
Sample_417612_4176 ALL diagnosis 133,53 97,39% 93,66% 91,36% 
Sample_220313_2203 ALL remission 100,09 97,17% 93,27% 90,07% 
Sample_NGS-163 ALL diagnosis 86,93 96,97% 92,66% 88,61% 
Sample_NGS-164 ALL remission 105,63 97,12% 93,09% 89,98% 
Sample_NGS-165 ALL diagnosis 105,30 97,12% 93,16% 89,88% 
Sample_NGS-166 ALL remission 118,13 97,21% 93,49% 90,70% 
Sample_NGS-167 ALL diagnosis 106,96 96,96% 92,98% 89,89% 
Sample_NGS-168 ALL remission 104,68 96,96% 93,01% 89,98% 
Sample_NGS-169 ALL diagnosis 113,20 97,20% 93,23% 90,28% 
Sample_NGS-170 ALL remission 113,99 97,01% 93,08% 90,07% 
Sample_NGS-171 ALL diagnosis 114,53 97,21% 93,39% 90,43% 
Sample_NGS-172 ALL remission 107,10 97,25% 93,40% 90,39% 
Sample_NGS-173 ALL diagnosis 91,97 97,14% 92,91% 89,22% 
Sample_NGS-174 ALL remission 99,24 97,12% 93,11% 89,80% 
Sample_NGS-175 ALL diagnosis 105,56 97,20% 93,20% 89,99% 
Sample_NGS-176 ALL remission 114,65 97,42% 93,52% 90,65% 
Sample_NGS-177 ALL diagnosis 105,37 97,09% 93,11% 90,09% 
Sample_NGS-178 ALL remission 125,59 97,97% 93,67% 91,10% 
Sample_NGS-179 ALL diagnosis 92,72 97,55% 92,81% 89,15% 
Sample_NGS-180 ALL remission 89,02 97,36% 92,78% 88,77% 
Sample_NGS-183 ALL diagnosis 118,25 97,40% 93,63% 90,80% 
Sample_NGS-185 ALL germline 105,03 97,02% 93,07% 89,94% 
  MEAN 86,54608696 96,73% 90,55% 84,09% 
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